[go: up one dir, main page]

EP2019688A2 - Use of cathepsin k antagonists in bone production - Google Patents

Use of cathepsin k antagonists in bone production

Info

Publication number
EP2019688A2
EP2019688A2 EP07797567A EP07797567A EP2019688A2 EP 2019688 A2 EP2019688 A2 EP 2019688A2 EP 07797567 A EP07797567 A EP 07797567A EP 07797567 A EP07797567 A EP 07797567A EP 2019688 A2 EP2019688 A2 EP 2019688A2
Authority
EP
European Patent Office
Prior art keywords
bone
cathepsin
inhibitor
cell
implant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07797567A
Other languages
German (de)
French (fr)
Inventor
Michael Long
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Velcura Therapeutics Inc
Original Assignee
Velcura Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Velcura Therapeutics Inc filed Critical Velcura Therapeutics Inc
Publication of EP2019688A2 publication Critical patent/EP2019688A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22038—Cathepsin K (3.4.22.38)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders

Definitions

  • the present invention relates to the fields of molecular biology and medicine.
  • it relates to the fields of bone disease & injury, bone repair,, bone implants, bone grafts and periodontal disease. Specifically, it deals with the use of Cathepsin K antagonists to promote bone formation.
  • Osteoporosis represents a large and rapidly growing health care problem with an unmet medical need for therapies that stimulate bone formation. Most current drugs for osteoporosis retard bone degradation but do not stimulate bone formation to replace already lost bone. Compounds that stimulate bone formation thus represent an unmet need in the area of bone disease. Osteoporosis is known to affect approximately 100 million people worldwide - 35 million of whom live in the U.S., Western Europe and Japan. Moreover, over 25 million individuals suffer bone fractures yearly, 60 million have periodontal disease (in which the tooth loosens from the jaw bone), and another 18 million have other bone disorders such as bone cancer.
  • bone reconstruction and, specifically, the ability to reconstruct defects in bone tissue that result from traumatic injury, as a consequence of cancer or cancer surgery, as a result of a birth defect, or as a result of aging.
  • orthopedic implants e.g., cranial and facial bone are particular targets for this type of reconstructive need.
  • new implant materials e.g., titanium
  • Titanium implants provide excellent temporary stability across bony defects.
  • experience has shown that a lack of viable bone bridging the defect can result in exposure of the appliance, infection, structural instability and, ultimately, failure to repair the defect.
  • Autologous bone grafts are another possibility to deal with bone injury, but they have several demonstrated disadvantages in that they must be harvested from a donor site such as iliac crest or rib, they usually provide insufficient bone to completely fill the defect, and the bone that does form is sometimes prone to infection and resorption.
  • Partially purified xenogeneic preparations are not practical for clinical use because microgram quantities are purified from kilograms of bovine bone, making large scale commercial production both costly and impractical. Allografts and demineralized bone preparations are therefore often employed. Microsurgical transfers of free bone grafts with attached soft tissue and blood vessels can close bony defects with an immediate source of blood supply to the graft.
  • a method of promoting bone formation comprising (i) selecting a first intracellular Cathepsin K inhibitor; and (ii) administering to a subject the first inhibitor of Cathepsin K.
  • the inhibitor may be a biological or an organopharmaceutical small molecule.
  • the biological may be a peptide, an siRNA, an antisense molecule or a single-chain antibody.
  • the organopharmaceutical small molecule may be a structural variant of a known Cathepsin K inhibitor based on hydrophilic and lipophilic characteristics, spatial properties, or other information available from medicinal chemistry and chemical enzymology studies on these compounds.
  • the organopharmaceutical may be an epoxysuccinamide, VEL-0230 or analog thereof.
  • the first inhibitor may also prevent bone resorption.
  • the subject may suffer from a bone-related pathology or injury, such as osteoporosis, vitamin D deficiency, bone cancer, bone fracture, periodontal disease, Paget' s disease, osteoporosis secondary to other diseases, or in need of bone grafts or implants.
  • the subject is a human or a non-human animal.
  • the compound may possess or lack bone resorption inhibition.
  • the method may further comprise contacting the subject with a second agent.
  • the second agent may be a bisphosphonate, a PTH analog, or a second inhibitor of Cathepsin K that is distinct from the first inhibitor.
  • the second inhibitor of Cathepsin K may be an extracellular inhibitor of Cathepsin K.
  • the first and/or second inhibitor may be formulated to increase transmembrane delivery.
  • the first and/or second inhibitor may be formulated with a cell permeability factor.
  • the first and/or second inhibitor may be formulated in a lipid delivery vehicle.
  • the first and/or second inhibitor may be formulated to enhance its bioavailability.
  • the first and/or second inhibitor may be administered to the subject more than once.
  • the first and/or second inhibitor is administered to the subject by oral or intravenous routes.
  • a method of producing bone from an isolated bone cell comprising (i) selecting an intracellular Cathepsin K inhibitor; (ii) contacting the bone cell with the inhibitor of Cathepsin K; and (iii) culturing the cell under conditions promoting bone formation.
  • the method may further comprise implanting the bone cell or bone derived therefrom in a subject.
  • the bone cell may have been obtained, prior to step (ii) from the subject.
  • the obtained cell may have been derived from a stem cell prior to step (ii).
  • the stem cell may have been under conditions promoting the formation of an osteogenic cell prior to step (ii).
  • the compound may possess or lack bone resorption inhibition.
  • a method of identifying an agent that promotes bone formation comprising (i) providing a candidate compound; (ii) admixing the candidate compound with an isolated Cathepsin K enzyme, or a cell expressing Cathepsin K, or an experimental animal, cells of which express Cathepsin
  • step (iii) measuring Cathepsin K activity or expression or bone formation; and (iv) comparing the characteristic measured in step (iii) with that observed in the absence of the candidate modulator, wherein a difference between the measured characteristic indicates that the candidate compound is, indeed, a modulator of Cathepsin K.
  • the compound may possess or lack bone resorption inhibition.
  • compositions and kits of the invention can be used to achieve methods of the invention.
  • FIG. 1 Ex vivo Bone Formation.
  • FIG. 2 Bone formation. Bone forming in tissue like aggregates of human osteoblasts is indicated by Ca 2+ fluorescence (arrows).
  • FIG. 4 Cell Lvsate versus Intact Cell IC50 Determinations for VEL-0230.
  • FIG. 5 Reduction of Cathepsin K mRNA by siRNAs.
  • FIG. 6 Reduction of Cathepsin K mRNA by siRNAs.
  • FIG. 7 - VEL-0230 Prevents Trabecular Bone Loss. N.B. Center panel is not “washed out”, but lacks bone that is red in this histochemical stain.
  • FIG. 8 - VEL-0230 Prevents Cortical Bone Loss.
  • FIG. 9 Osteocalcin. BSAP & BMP Levels in VEL-0230-treated Primates.
  • FIG. 10 Non-supervised Hierarchical Clustering of Gene Expression
  • FIG. 11 Families of Genes Involved in Ex vivo Bone Formation.
  • the inventor has demonstrated bone formation in tissue culture using methodology described in U.S. Patent 6,811,786, included herein by reference. Using this system, he has discovered a unique mechanism of action for Cathepsin K, a proteolytic enzyme previously thought to be involved only in bone degradation. Its role in modulating bone resorption is that of a classic proteolytic enzyme, functioning to degrade components of the extra-cellular compartment, particularly collagen (Bossard et al, 1996).
  • this enzyme functions solely and/or selectively in osteoclasts to degrade extracellular proteins and, as such, is targeted by anti-catabolic therapies that function to inhibit the bone- resorbing osteoclast (Yasuda et al, 2005; Grabowskal et al, 2005; Troen, 2004; Dodds, 2003; Zaidi et al, 2003).
  • Cathepsin K was shown to be expressed by osteoblasts; however, this report still subscribed to the concept that Cathepsin K has an extracellular role and, further, did not test enzymatic function of this enzyme within osteoblasts (Mandelin et al, 2006).
  • Cathepsin K plays a role in bone formation as inhibition of the enzyme unexpectedly results in an increase in bone formation, as described below.
  • the role of Cathepsin K in bone formation intracellular signaling networks is supported by three observations: (1) the inventor's Cathepsin K inhibitors stimulate bone formation both in vivo and in vitro, (2) RNA interference studies of Cathepsin K (RNAi; performed via small- interfering RNA (siRNA) treatment) demonstrate that inhibition of this message results in a bone-formation phenotype in treated human osteoblasts, and (3) stimulation of bone formation with multiple osteogenic growth factors decreases Cathepsin K message and activity within the osteoblast.
  • RNAi RNA interference studies of Cathepsin K
  • siRNA small- interfering RNA
  • Cathepsin K Cathepsins are proteases that function in the normal physiological as well as pathological degradation of connective tissue. Cathepsins play a major role in intracellular protein degradation and turnover, bone remodeling, and prohormone activation (Marx, 1987). Cathepsin B, H, L and S are ubiquitously expressed lysosomal cysteine proteinases that belong to the papain superfamily. They are found at constitutive levels in many tissues in the human including kidney, liver, lung and spleen. Some pathological roles of cathepsins include an involvement in glomerulonephritis, arthritis, and cancer metastasis (Sloan and Honn, 1984). Greatly elevated levels of cathepsin L and B mRNA and protein are seen in tumor cells. Cathepsin L mRNA is also induced in fibroblasts treated with tumor promoting agents and growth factors (Kane and Gottesman, 1990).
  • Cathepsin K a member of this protease family, is considered the primary protease responsible for the degradation of the bone matrix.
  • Cathepsin K was discovered in 1994, is synthesized as a 37 kDa pre-pro enzyme, and is presumably autoactivated to the mature 27 kDa enzyme at low pH (McQueney et ah, 1997; Littlewood-Evans et al, 1997; U.S. Patent 5,861,298). It is abundantly and relatively selectively expressed in osteoclasts, where it is localized in lysosomes in the ruffled border and in resorption lacunae on the bone surface.
  • the U.S. Patents 5,843,992, 6,387,908 and 6,689,785, incorporated by reference, are drawn to the structures underlying VEL-0230 and its analogues as Cathepsin K inhibitors and their use in osteoporosis, malignant hypercalcemia, Paget' s Disease, and arthritis.
  • the only known activity of Cathepsin K antagonists is to modulate the extracellular activity of Cathepsin K.
  • An agent of the present invention is one that is capable of inhibiting the extracellular function of Cathepsin K and also promoting the formation of bone in vitro and/or in vivo by the inhibition of intracellular Cathepsin K within the osteoclast.
  • the agent may also inhibit bone resorption.
  • the effect of these molecular and cellular actions will be to treat bone disease and injury and to improve the function in the clinical situation (reduction in pain, increase in mobility, etc.) of a subject suffering from bone-related pathologies.
  • agents may be used in combination with intracellular Cathepsin K inhibitors. More generally, these agents would be provided in a combined amount (along with the intracellular inhibitor) to produce any of the effects discussed above.
  • This process may involve contacting the cell or subject with both agents at the same time. This may be achieved by contacting the cell with a single composition or pharmacological formulation that includes both agents, or by contacting the cell or subject with two distinct compositions or formulations, at the same time, wherein one composition includes the intracellular inhibitor and the other includes the second agent.
  • one agent may precede or follow the other by intervals ranging from minutes to weeks.
  • the agents are applied separately to the cell or subject, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the agents would still be able to exert an advantageously combined effect on the cell or subject.
  • the intracellular inhibitor of Cathepsin K is "A” and the other agent is "B":
  • Combination agents include bisphosphonates (DidronelTM, FosamaxTM and ActonelTM), SERMs (Evista) or other hormone derivatives, and Parathyroid Hormone (PTH) analogs.
  • PTH Parathyroid Hormone
  • U.S. Patents 6,642,239, 6,531,612, 6,462,076 and 6,274,336, as well as U.S. Publication Nos. 2006/0074092, 2006/0020001, 2005/0245596, 2005/0107616, 2005/0054819, and 2004/0249153 disclose other Cathepsin K inhibitors that work in an extracellular fashion.
  • Fracture The first example is the otherwise healthy individual who suffers a fracture. Often, clinical bone fracture is treated by casting to alleviate pain and allow natural repair mechanisms to repair the wound. There has been progress in the treatment of fracture in recent times, however, even without considering the various complications that may arise in treating fractured bones, any new procedures to increase bone healing in normal circumstances would represent a great advance.
  • Periodontal Disease Progressive periodontal disease leads to tooth loss through destruction of the tooth's attachment to the surrounding bone. Approximately 5 - 20% of the U.S. population (15-60 million individuals) suffers from severe generalized periodontal disease, and there are 2 million related surgical procedures. Moreover, if the disease is defined as the identification of at least one site of clinical attachment loss, then approximately 80% of all adults are affected, and 90% of those aged 55 to 64 years. If untreated, approximately 88% of affected individuals show moderate to rapid progression of the disease' which shows a strong correlation with age. The major current treatment for periodontal disease is regenerative therapy consisting of replacement of lost periodontal tissues. The lost bone is usually treated with an individual's own bone and bone marrow, due to their high osteogenic potential.
  • Bone allografts (between individuals) can also be performed using stored human bone. Although current periodontal cost analyses are hard to obtain, the size of the affected population and the current use of bone grafts as a first-order therapy strongly suggest that this area represents an attractive target for bone-building therapies.
  • Osteopenia/osteoporosis refers to a heterogeneous group of disorders characterized by decreased bone mass and fractures.
  • Osteopenia is a bone mass that is one or more standard deviations below the mean bone mass for a population; osteoporosis is defined as 2.5 SD or lower.
  • An estimated 20-25 million people are at increased risk for fracture because of site-specific bone loss.
  • Risk factors for osteoporosis include increasing age, gender (more females), low bone mass, early menopause, race (Caucasians in general; asian and hispanic females), low calcium intake, reduced physical activity, genetic factors, environmental factors (including cigarette smoking and abuse of alcohol or caffeine), and deficiencies in neuromuscular control that create a propensity to fall.
  • osteoporosis is a significant health care problem.
  • Osteoporosis once thought to be a natural part of aging among women, is no longer considered age or gender-dependent. Osteoporosis is defined as a skeletal disorder characterized by compromised bone strength predisposing to an increased risk of fracture. Bone strength reflects the integration of two main features: bone density and bone quality. Bone density is expressed as grams of mineral per area or volume and in any given individual is determined by peak bone mass and amount of bone loss. Bone quality refers to architecture, turnover, damage accumulation (e.g., microfractures) and mineralization. A fracture occurs when a failure-inducing force (e.g. , trauma) is applied to osteoporotic bone.
  • a failure-inducing force e.g. , trauma
  • Bone Reconstruction/Grafting A fourth example is related to bone reconstruction and, specifically, the ability to reconstruct defects in bone tissue that result from traumatic injury; as a consequence of cancer or cancer surgery; as a result of a birth defect; or as a result of aging.
  • implant materials e.g., titanium
  • Titanium implants provide excellent temporary stability across bony defects.
  • experience has shown that a lack of viable bone bridging the defect can result in exposure of the appliance to infection, structural instability and, ultimately, failure to repair the defect.
  • a therapeutic agent that stimulates bone formation on or around the implant will facilitate more rapid recovery.
  • Autologous bone grafts are another possibility, but they have several demonstrated disadvantages in that they must be harvested from a donor site such as iliac crest or rib, they usually provide insufficient bone to completely fill the defect, and the bone that does form is sometimes prone to infection and resorption. Partially purified xenogeneic preparations are not practical for clinical use because microgram quantities are purified from kilograms of bovine bone, making large scale commercial production both costly and impractical. Allografts and demineralized bone preparations are therefore often employed.
  • Microsurgical transfers of free bone grafts with attached soft tissue and blood vessels can close bony defects with an immediate source of blood supply to the graft.
  • these techniques are time consuming, have been shown to produce a great deal of morbidity, and can only be used by specially trained individuals.
  • the bone implant is often limited in quantity and is not readily contoured. In the mandible, for example, the majority of patients cannot wear dental appliances using presently accepted techniques (even after continuity is established), and thus gain little improvement in the ability to masticate.
  • compositions of the present invention comprise an effective amount of one or more Cathepsin K antagonists dissolved or dispersed in a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate.
  • the preparation of a pharmaceutical composition that contains at least one Cathepsin K antagonist, and optionally an additional active ingredient, will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, incorporated herein by reference.
  • preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biological Standards.
  • pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329, incorporated herein by reference). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the pharmaceutical compositions is contemplated.
  • the Cathepsin K antagonist may be admixed with different types of carriers depending on whether it is to be administered orally or by injection.
  • the present invention can be administered buccally, intravenously, intradermally, transdermally, intrathecally, intraarterially, intraperitoneally, intranasally, intravaginally, intrarectally, topically, intramuscularly, subcutaneously, mucosally, orally, topically, locally, inhalation (e.g., aerosol inhalation), injection, infusion, continuous infusion, localized perfusion bathing target cells directly, via a catheter, via a lavage, in cremes, in lipid compositions (e.g., nanoparticles, liposomes), or by other method or any combination of the forgoing as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, incorporated herein by reference).
  • the Cathepsin K antagonist may be formulated into a composition in a free base, neutral or salt form.
  • Pharmaceutically acceptable salts include the acid addition salts, e.g., those formed with the free amino groups of a proteinaceous composition, or which are formed with inorganic acids such as for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, fumaric, or mandelic acid. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as for example, sodium, potassium, ammonium, calcium or ferric hydroxides; or such organic bases as isopropylamine, trimethylamine, histidine or procaine. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
  • the composition of the present invention suitable for administration is provided in a pharmaceutically acceptable carrier with or without an inert diluent.
  • the carrier should be assimilable and includes liquid, semi-solid, i.e., pastes, or solid carriers. Except insofar as any conventional media, agent, diluent or carrier is detrimental to the recipient or to the therapeutic effectiveness of the composition contained therein, its use in administrable composition for use in practicing the methods of the present invention is appropriate.
  • carriers or diluents include fats, oils, water, saline solutions, lipids, liposomes, resins, binders, fillers and the like, or combinations thereof.
  • composition may also comprise various antioxidants to retard oxidation of one or more component. Additionally, the prevention of the action of microorganisms can be brought about by preservatives such as various antibacterial and antifungal agents, including but not limited to parabens (e.g., methylparabens, propylparabens), chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof.
  • parabens e.g., methylparabens, propylparabens
  • chlorobutanol phenol
  • sorbic acid thimerosal or combinations thereof.
  • the composition is combined or mixed thoroughly with a semi-solid or solid carrier.
  • the mixing can be carried out in any convenient manner such as grinding.
  • Stabilizing agents can be also added in the mixing process in order to protect the composition from loss of therapeutic activity, i.e., denaturation in the stomach.
  • stabilizers for use in an the composition include buffers, amino acids such as glycine and lysine, carbohydrates such as dextrose, mannose, galactose, fructose, lactose, sucrose, maltose, sorbitol, mannitol, etc.
  • the present invention may concern the use of a pharmaceutical lipid vehicle compositions that include Cathepsin K antagonist, one or more lipids, and an aqueous solvent.
  • lipid will be defined to include any of a broad range of substances that is characteristically insoluble in water and extractable with an organic solvent. This broad class of compounds are well known to those of skill in the art, and as the term "lipid” is used herein, it is not limited to any particular structure. Examples include compounds which contain long- chain aliphatic hydrocarbons and their derivatives. A lipid may be naturally- occurring or synthetic (i.e., designed or produced by man).
  • Lipids are well known in the art, and include for example, neutral fats, phospholipids, phosphoglycerides, steroids, terpenes, lysolipids, glycosphingolipids, glycolipids, sulphatides, lipids with ether and ester-linked fatty acids and polymerizable lipids, and combinations thereof.
  • the Cathepsin K antagonist may be dispersed in a solution containing a lipid, dissolved with a lipid, emulsified with a lipid, mixed with a lipid, combined with a lipid, covalently bonded to a lipid, contained as a suspension in a lipid, contained or complexed with a micelle or liposome, or otherwise associated with a lipid or lipid structure by any means known to those of ordinary skill in the art.
  • the dispersion may or may not result in the formation of liposomes.
  • the actual dosage amount of a composition of the present invention administered to an animal patient can be determined by physical and physiological factors such as body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, idiopathy of the patient and on the route of administration. Depending upon the dosage and the route of administration, the number of administrations of a preferred dosage and/or an effective amount may vary according to the response of the subject. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject.
  • Cathepsin K antagonist pharmaceutical compositions may comprise, for example, at least about 0.1% of the antagonist, about 0.5% of the antagonist, or about 1.0% of the antagonist, hi other embodiments, the antagonist may comprise between about 2% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein.
  • the amount of the antagonist in each therapeutically useful composition may be prepared is such a way that a suitable dosage will be obtained in any given unit dose of the compound.
  • a dose of a Cathepsin K antagonist may also comprise from about 0.1 microgram/kg/body weight, about 0.2 microgram/kg/body weight, about 0.5 microgram/kg/body weight, about 1 microgram/kg/body weight, about 5 microgram/kg/body weight, about 10 microgram/kg/body weight, about 50 microgram/kg/body weight, about 100 microgram/kg/body weight, about 200 microgram/kg/body weight, about 350 microgram/kg/body weight, about 500 microgram/kg/body weight, about 1 milligram/kg/body weight, about 5 milligram/kg/body weight, about 10 milligram/kg/body weight, about 50 milligram/kg/body weight, about 100 milligram/kg/body weight, about 200 milligram/kg/body weight, about 350 milligram/kg/body weight, about 500 milligram/kg/body weight, to about 1000 mg/kg/body weight or more per administration, and any range derivable therein, hi non-limiting examples of
  • the Cathepsin K antagonists are formulated to be administered via an alimentary route.
  • Alimentary routes include all possible routes of administration in which the composition is in direct contact with the alimentary tract.
  • the pharmaceutical compositions disclosed herein may be administered orally, buccally, rectally, or sublingually.
  • these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard- or soft- shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.
  • the active compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like (Mathiowitz et al., 1997; Hwang et al, 1998; U.S. Patents 5,641,515, 5,580,579 and 5,792, 451, each specifically incorporated herein by reference in its entirety).
  • the tablets, troches, pills, capsules and the like may also contain the following: a binder, such as, for example, gum tragacanth, acacia, cornstarch, gelatin or combinations thereof; an excipient, such as, for example, dicalcium phosphate, mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate or combinations thereof; a disintegrating agent, such as, for example, corn starch, potato starch, alginic acid or combinations thereof; a lubricant, such as, for example, magnesium stearate; a sweetening agent, such as, for example, sucrose, lactose, saccharin or combinations thereof; a flavoring agent, such as, for example peppermint, oil of wintergreen, cherry flavoring, orange flavoring, etc.
  • a binder such as, for example, gum tragacanth, acacia, cornstarch, gelatin or combinations thereof
  • an excipient such as, for
  • the dosage unit form When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar, or both. When the dosage form is a capsule, it may contain, in addition to materials of the above type, carriers such as a liquid carrier. Gelatin capsules, tablets, or pills may be enterically coated. Enteric coatings prevent denaturation of the composition in the stomach or upper bowel where the pH is acidic. See, e.g., U.S. Patent 5,629,001.
  • the basic pH therein dissolves the coating and permits the composition to be released and absorbed by specialized cells, e.g., epithelial enterocytes and Peyer's patch M cells.
  • a syrup of elixir may contain the active compound sucrose as a sweetening agent methyl and propylparabens as preservatives, a dye and flavoring, such as cherry or orange flavor.
  • any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
  • the active compounds may be incorporated into sustained-release preparation and formulations.
  • compositions of the present invention may alternatively be incorporated with one or more excipients in the form of a mouthwash, dentifrice, buccal tablet, oral spray, gel or sublingual orally-administered formulation.
  • a mouthwash may be prepared incorporating the active ingredient in the required amount in an appropriate solvent, such as a sodium borate solution (Dobell's Solution).
  • the active ingredient may be incorporated into an oral solution such as one containing sodium borate, glycerin and potassium bicarbonate, or dispersed in a dentifrice, or added in a therapeutically-effective amount to a composition that may include water, binders, abrasives, flavoring agents, foaming agents, and humectants.
  • a composition may include water, binders, abrasives, flavoring agents, foaming agents, and humectants.
  • the compositions may be fashioned into a tablet, gel or solution form that may be placed under the tongue, along the gum line, brushed on to teeth surfaces, or otherwise dissolved in the mouth.
  • U.S. Patents 6,074,674 and 6,270,750 both incorporated by reference, describe topical, sustained release compositions for periodontal procedures .
  • Cathepsin K antagonist may be administered via a parenteral route.
  • parenteral includes routes that bypass the alimentary tract.
  • the pharmaceutical compositions disclosed herein may be administered for example, but not limited to intravenously, intradermally, intramuscularly, intraarterially, intrathecally, subcutaneous, or U.S. Patents 6,537,514, 6,613,308, 5,466,468, 5,543,158; 5,641,515; and 5,399,363 (each specifically incorporated herein by reference in its entirety).
  • Solutions of the active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.
  • Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (U.S. Patent 5,466,468, specifically incorporated herein by reference in its entirety), hi all cases the form must be sterile and must be fluid to the extent that easy injectability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (i.e., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils.
  • polyol i.e., glycerol, propylene glycol, and liquid polyethylene glycol, and the like
  • suitable mixtures thereof and/or vegetable oils.
  • Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • aqueous solutions For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
  • aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration.
  • sterile aqueous media that can be employed will be known to those of skill in the art in light of the present disclosure.
  • one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences” 15th Edition, pages 1035-1038 and 1570-1580).
  • Sustained release formulations for treating of bone conditions include U.S. Patents 4,722,948, 4,843,112, 4,975,526, 5,085,861, 5,162,114, 5,741,796 and 6,936,270, all of which are incorporated by reference.
  • Methods and injectable compositions for bone repair are described in U.S. Patents 4,863,732, 5,531,791, 5,840,290, 6,281,195, 6,288,043, 6,485,754, 6,662,805 and 7,008,433, all of which are incorporated by reference.
  • Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile- filtered solution thereof.
  • a powdered composition is combined with a liquid carrier such as, e.g., water or a saline solution, with or without a stabilizing agent.
  • Cathepsin K inhibitors may be used in the context of devices, such as implants.
  • a variety of bone related implants are contemplated, including dental implants, joint implants such as hips, knees, and elbows, vertebral/spinal implants, and others.
  • the Cathepsin K inhibitor may be impregnated in a surface of the implant, including in a bioactive matrix or coating.
  • the inhibitor may further formulated to sustained, delayed, prolonged or time release.
  • the coating may comprise polymers, for example, such as those listed below in Section V.
  • U.S. Patents relating to bone implants and devices which may be utilized in accordance with this embodiment of the invention:
  • Bone implant in particular, an inter-vertebral implant
  • Implant materials having a phosphatase and an organophosphorus compound for in vivo mineralization of bone
  • Bone stabilization implant having a bone plate portion with integral cable clamping means
  • stem cells are provided that may be treated to produce osteogenic cells.
  • Stem cells are generally defined as pluripotent cells that may be induced to differentiate into a particular cell type - in this case, bone forming cells.
  • Various stem cells may be utilized in accordance with the present invention, and include mesenchymal stem cells, hematopoietic stem cells, embryonic stem cells, tissue stem cells, and embryonic carcinoma cells. These cells can be isolated by a variety of methods well known in the art, including immunological isolation, physico-chemical isolation, fluorescent activated cell sorting, limiting dilution culture, etc.
  • bone precursor cells are produced from stem cells.
  • a bone precursor cell is any cell that is capable of differentiating or expanding into an osteoblast cell. The following section describes the characteristics of these cells.
  • Osteogenic or precursor cells are derived from primary sources such as bone marrow or bone.
  • cells can be derived from several different species, including cells of human, bovine, equine, canine, feline and murine origin.
  • Bone Precursor Cells Human bone precursor cells are characterized as small-sized cells that express low amounts of bone proteins (osteocalcin, osteonectin, and alkaline phosphatase) and have a low degree of internal complexity (Long et al, 1995). When stimulated to differentiate, these preosteoblast cells become osteoblast in their appearance, size, antigenic expression, and internal structure. Although these cells are normally present at very low frequencies in bone marrow, a process for isolating these cells has been described (Long et al, 1995).
  • U.S. Patent 5,972,703 further describes methods of isolating and using bone precursor cells, and is specifically incorporated herein by reference.
  • MSC mesenchymal stem cells
  • Preosteoblasts are intermediate between osteoprogenitor cells and osteoblasts.
  • Osteoblasts are differentiated cells of the bone- forming cell lineage. They are large cells, possessing a eccentric nucleus, and produce of the extracellular proteins required for bone formation. They can be obtained from bone as populations of both preosteoblasts and osteoblasts as described in U.S. Serial No. 09/753,043, which is specifically incorporated herein by reference.
  • Cell culture may be employed using serum-free media for growth of bone- producing cells, and the subsequent conversion of stem cells into bone-forming osteogenic or osteoprogenitor cells.
  • serum-free media for growth of bone- producing cells, and the subsequent conversion of stem cells into bone-forming osteogenic or osteoprogenitor cells.
  • the following section describes attributes and conditions for using serum- free media. See also U.S. Patent 6,811,776.
  • the use of serum-free culture for the manufacture of recombinant biopharmaceuticals from mammalian cells has been thoroughly reviewed (Barnes, 1987; Barnes & Sam, 1980; Broad et al, 1991; Jayme, 1991).
  • the list of the main additives which are used as supplements for serum-free media is summarized by Barnes (1987) and Barnes & Sam (1980).
  • Most commercially available serum-free media contain a carrier protein such as albumin. The presence of carrier protein might be required for protection of the cell viability.
  • serum free culture medium can be found in U.S. Patent 5,063,157, herein incorporated by reference.
  • the media comprises, in addition to the base medium, transferrin, insulin, a peptone, a ⁇ -D-xylopyranose derivative, selenite and a biological polyamine.
  • Another serum free cell growth medium for mammalian cells is disclosed in U.S. Patent 4,443,546.
  • This growth medium in addition to the basic medium, contains seven ingredients.
  • EPA 481 791 discloses a culture medium for CHO cells comprising water, an osmolality regulator, a buffer, an energy source, amino acids, an iron source, a growth factor and other optional components.
  • the two media exemplified contain 19 and 17 components, respectively. Examples of potential additives to serum free media follow below.
  • Albumin is preferably supplied in the form of bovine (BSA) or human serum albumin (HSA) in an effective amount for the growth of cells.
  • BSA bovine
  • HSA human serum albumin
  • Albumin provides a source of protein in the media.
  • Albumin is thought to act as a carrier for trace elements and essential fatty acids.
  • the albumin used in the present formulations is free of pyrogens and viruses, and when necessary, is approved regulatory agencies for infusion into human patients.
  • the HSA may be deionized using resin beads prior to use.
  • the concentration of human serum albumin is 1-8 mg/ml, preferably 3-5 mg/ml, most preferably 4 mg/ml.
  • Soluble Carrier/Fatty Acid Complex The albumin mentioned above could be substituted by a soluble carrier/essential fatty acid complex and a soluble carrier cholesterol complex which can effectively deliver the fatty acid and cholesterol to the cells.
  • An example of such a complex is a cyclodextrin/linoleic acid, cholesterol and oleic acid complex. This is advantageous as it would allow for the replacement of the poorly characterized albumin with a well defined molecule.
  • the use of cyclodextrin removes the need for the addition of human/animal serum albumin, thereby eliminating any trace undesired materials which the albumin would introduce into the media.
  • the use of cyclodextrin simplifies the addition of specific lipophilic nutrients to a serum-free culture.
  • the lipophilic substances which can be complexed with cyclodextrin include unsaturated fatty acids such as linoleic acid, cholesterol and oleic acid.
  • unsaturated fatty acids such as linoleic acid, cholesterol and oleic acid.
  • the linoleic acid, cholesterol and oleic acid are present in effective amounts and can be present in equal proportions such that the total amount is 0.001 to 100 ⁇ g/ml, preferably 0.1 to 10 ⁇ g/ml.
  • the preparation of such complexes is known in the art and is described, for example, in U.S. Patent 4,533,637, the entire contents of which is hereby incorporated by reference.
  • Iron Source A source of iron in an effective amount and in a form that can be utilized by the cells can be added to the media.
  • the iron can be supplied by saturating transferrin, its carrier molecule, in an effective amount.
  • the transferrin may be derived from animal sera or recombinantly synthesized. It is understood that when transferrin is derived from an animal source, it is purified to remove other animal proteins, and thus is usually at least 99% pure.
  • the transferrin concentration is usually between 80 and 500 ⁇ g/ml, preferably between 120 and 500 ⁇ g/ml, more preferably between 130 and 500 ⁇ g/ml, even more preferably between 275 and 400 ⁇ g/ml and most preferably 300 ⁇ g/ml.
  • An iron salt preferably a water soluble iron salt, such as iron chloride (e.g., FeCl 3 .6H 2 O) dissolved in an aqueous solution such as an organic acid solution (e.g. , citric acid) is used to supply the iron to transferrin.
  • iron chloride e.g., FeCl 3 .6H 2 O
  • organic acid solution e.g. , citric acid
  • concentration of iron chloride is 0.0008 to 8 ⁇ g/ml, preferably 0.08 to 0.8 ⁇ g/ml, most preferably 0.08 ⁇ g/ml.
  • Insulin Growth Factor Insulin also may be added to the media of the present invention in an effective amount.
  • insulin like growth factor such as insulin like growth factor 1 and insulin like growth factor 2 may be used in place of or in addition to insulin in an amount which provides substantially the same result as a corresponding amount of insulin.
  • insulin growth factor includes both insulin and insulin like growth factors.
  • lipids lipids that are preferably not added unless they are necessary for a particular experiment or to grow a particular type of cell.
  • triglycerides and/or phospholipids may be included as additional sources of lipid.
  • a preferable source of lipid contains a mixture of neutral triglycerides of predominantly unsaturated fatty acids such as linoleic, oleic, palmitic, linolenic, and stearic acid. Such a preparation may also contain phosphatidylethanolamine and phosphatidylcholine.
  • Another source of lipid is a human plasma fraction precipitated by ethanol and preferably rendered virus free by pasteurization.
  • the media When the media is to be used to grow cells for introduction into a human patient, the media preferably does not contain ingredients such as bovine serum albumin, mammalian serum, and/or any natural proteins of human or mammalian origin (as explained above). It is preferable that recombinant or synthetic proteins, if they are available and of high quality, are used. Most preferably, the amino acid sequences of the recombinant or synthetic proteins are identical to or highly homologous with those of humans. Thus, the most preferable serum-free media formulations herein contain no animal-derived proteins and do not have even a non-detectable presence of animal protein. In the most ideal system, optional components which are not necessary are preferably not added to the medium.
  • ingredients such as bovine serum albumin, mammalian serum, and/or any natural proteins of human or mammalian origin (as explained above). It is preferable that recombinant or synthetic proteins, if they are available and of high quality, are used. Most preferably, the amino acid sequences of the
  • Such optional components are described in the prior art cited above and may be selected from the group consisting of meat extract, peptone, phosphatidylcholine, ethanolamine, anti-oxidants, deoxyribonucleosides, ribonucleosides, soy bean lecithin, corticosteroids, myoinositol, monothioglycerol, and bovine or other animal serum albumin.
  • bone cells stimulated with Cathepsin K antagonists of the present invention may be used for autologous or heterologous transplant into subjects in need thereof.
  • supports will be used to provide a scaffold or matrix over with bone cells and grown and deposit bone.
  • polymeric materials including in vivo medical applications. These materials are well suited to implantation as they can serve as a temporary scaffold to be replaced by host tissues, degrade by hydrolysis to non-toxic products, and be excreted, as described by Kulkarni et al. (1971) and Hollinger and Battistone (1986).
  • Either natural or synthetic polymers can be used to form the matrix, although synthetic polymers are preferred for reproducibility and controlled release kinetics.
  • Synthetic polymers that can be used include bioerodible polymers such as poly(lactide) (PLA), poly(glycolic acid) (PGA), poly(lactide-co-glycolide) (PLGA), and other poly(alpha-hydroxy acids), poly(caprolactone), polycarbonates, polyamides, polyanhydrides, polyamino acids, polyortho esters, polyacetals, polycyanoacrylates and degradable polyurethanes, and non-erodible polymers such as polyacrylates, ethylene-vinyl acetate polymers and other acyl substituted cellulose acetates and derivatives thereof, non-erodible polyurethanes, polystyrenes, polyvinyl chloride, polyvinyl fluoride, poly( vinyl imidazole), chlorosulphonated polyolifins, polyethylene oxide, polyviny
  • non-degradable materials can be used to form the matrix or a portion of the matrix, they are not preferred.
  • natural polymers include proteins such as albumin, fibrin or fibrinogen, collagen, synthetic polyamino acids, and prolamines, and polysaccharides such as alginate, heparin, and other naturally occurring biodegradable polymers of sugar units.
  • PDS poly(paradioxanone)
  • PLA poly(lactic acid)
  • PGA poly(glycolic acid)
  • PLAGA copolymers. Copolymerization enables modulation of the degradation time of the material. By changing the ratios of crystalline to amorphous polymers during polymerization, properties of the resulting material can be altered to suit the needs of the application.
  • These polymers, including poly(lactide-co-glycolic) acid (PLGA) have been used as polymer composites for bone replacement as reported by Elgendy et al. (1993). Substituted polyphosphazenes have been shown to support osteogenic cell growth, as reported by Laurencin et al. (1993).
  • Poly(organophosphazenes) are high molecular weight polymers containing a backbone of alternating phosphorus and nitrogen atoms.
  • polyphosphazenes each derived from the same precursor polymer, poly(dichlorophosphazene).
  • the chlorine-substituted species can be modified by replacement of the chlorine atoms by different organic nucleophiles such as o-methylphenoxide along with amino acids.
  • the physical and chemical properties of the polymer can be altered by adding various ratios of hydrolytic sensitive side chains such as ethyl glycinate, as described by Wade et al. (1978) and Allcock and Fuller (1981). This will affect the degradation of the polymer as an implantable and biodegradable material as well as vary the support of osteogenic cells for bone and tissue implants, as shown by Laruencin et al (1993).
  • PLA, PGA and PLA/PGA copolymers are particularly useful for forming the biodegradable matrices.
  • PLA polymers are usually prepared from the cyclic esters of lactic acids. Both L(+) and D(-) forms of lactic acid can be used to prepare the PLA polymers, as well as the optically inactive DL-lactic acid mixture of D(-) and L(+) lactic acids.
  • Methods of preparing polylactides are well documented in the patent literature. The following U.S. Patents, the teachings of which are hereby incorporated by reference, describe in detail suitable polylactides, their properties and their preparation: U.S.
  • PGA is the homopolymer of glycolic acid (hydroxyacetic acid).
  • glycolic acid hydroxyacetic acid
  • glycolic acid is initially reacted with itself to form the cyclic ester glycolide, which in the presence of heat and a catalyst is converted to a high molecular weight linear-chain polymer.
  • PGA polymers and their properties are described in more detail in "Cyanamid Research Develops World's First Synthetic Absorbable Suture,” Chemistry and Industry, 905 (1970).
  • the erosion of the matrix is related to the molecular weights of PLA, PGA or PLA/PGA.
  • Poly(lactide-co-glycolide) (50:50) degrades in about six weeks following implantation. All polymers for use in the matrix must meet the mechanical and biochemical parameters necessary to provide adequate support for the cells with subsequent growth and proliferation.
  • the polymers can be characterized with respect to mechanical properties such as tensile strength using an Instron tester, for polymer molecular weight by gel permeation chromatography (GPC), glass transition temperature by differential scanning calorimetry (DSC) and bond structure by infrared (IR) spectroscopy, with respect to toxicology by initial screening tests involving Ames assays and in vitro teratogenicity assays, and implantation studies in animals for immunogenicity, inflammation, release and degradation studies. These polymers are particularly useful in forming fibrous or sponge type matrices for implantation. Polymers can also be used to form hydrogels in which the cells are suspended and then implanted.
  • GPC gel permeation chromatography
  • DSC differential scanning calorimetry
  • IR infrared
  • Matrix Materials Another class of materials for making the matrix is hydroxyapatite, or a similar ceramic formed of tricalcium phosphate (TCP) or calcium phosphate (CaPO 4 ). Calcium hydroxyapatites occur naturally as geological deposits and in normal biological tissues, principally bone, cartilage, enamel, dentin, and cementum of vertebrates and in many sites of pathological calcifications such as blood vessels and skin.
  • TCP tricalcium phosphate
  • CaPO 4 calcium phosphate
  • Synthetic calcium hydroxyapatite is formed in the laboratory either as pure Caio (PO 4 ) 6 (OH) 2 or hydroxyapatite that is impure, containing other ions such as carbonate, fluoride, chloride for example, or crystals deficient in calcium or crystals in which calcium is partly or completely replaced by other ions such as barium, strontium and lead.
  • other ions such as carbonate, fluoride, chloride for example
  • the crystals of pure synthetic apatites, geological apatites and many impure synthetically produced apatites are larger and more crystalline than the biological crystals of bone, dentin, cementum and cartilage.
  • the crystals of bone, dentin and cementum are very small, irregularly shaped, very thin plates whose rough average dimensions are approximately 10 to 50 angstroms in thickness, 30 to 150 angstroms in width, and 200 to 600 angstroms in length.
  • the synthetic materials are highly diverse, as reported in the literature. For example, the characterization of four commercial apatites was reported by Pinholt et al. (1992); Marden et al. (1990) reports on a protein, biodegradable material; Pinholt et al.
  • hydroxyapatite As used herein, all of these materials are generally referred to as "hydroxyapatite.”
  • the hydroxyapatite is particles having a diameter between approximately ten and 100 ⁇ m in diameter, most preferably about 50 ⁇ m in diameter.
  • Another form of hydroxyapatite scaffold is devitalized coral as a scaffold. Le Guehennec et al. (2004); Chen et al. (2004); Devecioglu et al. (2004); Kujala et ⁇ /. (2004).
  • Calcium phosphate ceramics can be used as implants in the repair of bone defects because these materials are non-toxic, non-immunogenic, and are composed of calcium and phosphate ions, the main constituents of bone (Frame, 1987; Parsons et al, 1988). Both tricalcium phosphate (TCP) Ca 3 (PO 4 ) 2 and hydroxyapatite (HA) Ca 1O (PO 4 ) ⁇ 5 (OH 2 ) have been widely used. Calcium phosphate implants are osteoinductive, and have the apparent ability to become directly bonded to bone. As a result, a strong bone-implant interface is created.
  • Calcium phosphate ceramics have a degree of bioresorbability which is governed by their chemistry and material structure. High density HA and TCP implants exhibit little resorption, while porous ones are more easily broken down by dissolution in body fluids and resorbed by phagocytosis. However, TCP degrades more quickly than HA structures of the same porosity in vitro. HA is relatively insoluble in aqueous environments. However, the mechanical properties of calcium phosphate ceramics make them ill-suited to serve as a structural element under load bearing circumstances. Ceramics are not preferred since they are brittle and have low resistance to impact loading.
  • Polymers that can form ionic hydrogels which are malleable can also be used to support the cells. Injecting a suspension of cells in a polymer solution may be performed to improve the reproducibility of cell seeding throughout a device, to protect the cells from shear forces or pressure induced necrosis, or to aid in defining the spatial location of cell delivery.
  • the injectable polymer may also be utilized to deliver ells and promote the formation of new tissue without the use of any other matrix.
  • the hydro gel is produced by cross-linking the ionic salt of a polymer with ions, whose strength increases with either increasing concentrations of ions or polymer.
  • the polymer solution is mixed with the cells to be implanted to form a suspension, which is then injected directly into a patient prior to polymerization of the suspension.
  • the suspension subsequently polymerizes over a short period of time due to the presence in vivo of physiological concentrations of ions such as calcium in the case where the polymer is a polysaccharide such as alginate.
  • a hydrogel is defined as a substance formed when an organic polymer (natural or synthetic) is cross-linked via covalent, ionic, or hydrogen bonds to create a three- dimensional open-lattice structure which entraps water molecules to form a gel.
  • materials which can be used to form a hydrogel include polysaccharides such as alginate, polyphosphazenes, and polyacrylates such as hydroxyethyl methacrylate (HEMA), which are cross-linked ionically, or block copolymers such as PluronicsTM or TetronicsTM, polyethylene oxide-polypropylene glycol block copolymers which are cross-linked by temperature or pH, respectively.
  • HEMA hydroxyethyl methacrylate
  • PluronicsTM or TetronicsTM polyethylene oxide-polypropylene glycol block copolymers which are cross-linked by temperature or pH, respectively.
  • Other materials include proteins such as fibrinogin, collagen, polymers such as polyvinylpyrrol
  • these polymers are at least partially soluble in aqueous solutions, such as water, buffered salt solutions, or aqueous alcohol solutions, that have charged side groups, or a monovalent ionic salt thereof.
  • aqueous solutions such as water, buffered salt solutions, or aqueous alcohol solutions
  • polymers with acidic side groups that can be reacted with cations are poly(phosphazenes), poly(acrylic acids), poly(methacrylic acids), copolymers of acrylic acid and methacrylic acid, poly(vinyl acetate), and sulfonated polymers, such as sulfonated polystyrene.
  • Copolymers having acidic side groups formed by reaction of acrylic or methacrylic acid and vinyl ether monomers or polymers can also be used.
  • Examples of acidic groups are carboxylic acid groups, sulfonic acid groups, halogenated (preferably fluorinated) alcohol groups, phenolic OH groups, and acidic OH groups.
  • Examples of polymers with basic side groups that can be reacted with anions are poly(vinyl amines), poly(vinyl pyridine), polyvinyl imidazole), and some imino substituted polyphosphazenes.
  • the ammonium or quaternary salt of the polymers can also be formed from the backbone nitrogens or pendant imino groups.
  • Examples of basic side groups are amino and imino groups.
  • Alginate can be ionically cross-linked with divalent cations, in water, at room temperature, to form a hydrogel matrix. Due to these mild conditions, alginate has been the most commonly used polymer for hybridoma cell encapsulation, as described, for example, in U.S. Patent 4,352,883. Described therein is an aqueous solution containing the biological materials to be encapsulated is suspended in a solution of a water soluble polymer, the suspension is formed into droplets which are configured into discrete microcapsules by contact with multivalent cations, then the surface of the microcapsules is cross-linked with polyamino acids to form a semipermeable membrane around the encapsulated materials.
  • the polyphosphazenes suitable for cross-linking have a majority of side chain groups which are acidic and capable of forming salt bridges with di- or trivalent cations.
  • preferred acidic side groups are carboxylic acid groups and sulfonic acid groups.
  • Hydrolyrically stable polyphosphazenes are formed of monomers having carboxylic acid side groups that are cross-linked by divalent or trivalent cations such as Ca 2+ or Al 3+ . Polymers can be synthesized that degrade by hydrolysis by incorporating monomers having imidazole, amino acid ester, or glycerol side groups.
  • Bioerodible polyphosphazenes have at least two differing types of side chains, acidic side groups capable of forming salt bridges with multivalent cations, and side groups that hydrolyze under in vivo conditions, e.g., imidazole groups, amino acid esters, glycerol and glucosyl.
  • the water soluble polymer with charged side groups is cross-linked by reacting the polymer with an aqueous solution containing multivalent ions of the opposite charge, either multivalent cations if the polymer has acidic side groups or multivalent anions if the polymer has basic side groups.
  • the preferred cations for cross-linking of the polymers with acidic side groups to form a hydrogel are divalent and trivalent cations such as copper, calcium, aluminum, magnesium, strontium, barium, and tin, although di-, tri- or tetra-functional organic cations such as alkylammonium salts can also be used.
  • Aqueous solutions of the salts of these cations are added to the polymers to form soft, highly swollen hydrogels and membranes.
  • the preferred anions for cross-linking of the polymers to form a hydrogel are divalent and trivalent anions such as low molecular weight dicarboxylic acids, for example, terepthalic acid, sulfate ions and carbonate ions. Aqueous solutions of the salts of these anions are added to the polymers to form soft, highly swollen hydrogels and membranes, as described with respect to cations.
  • polycations can be used to complex and thereby stabilize the polymer hydrogel into a semi-permeable surface membrane.
  • materials that can be used include polymers having basic reactive groups such as amine or imine groups, having a preferred molecular weight between 3,000 and 100,000, such as polyethylenimine and polylysine. These are commercially available.
  • One polycation is poly(L-lysine)
  • examples of synthetic polyamines are polyethyleneimine, poly(vinylamine), and poly(allyl amine).
  • polysaccharide, chitosan There are also natural polycations such as the polysaccharide, chitosan.
  • Polyanions that can be used to form a semi-permeable membrane by reaction with basic surface groups on the polymer hydrogel include polymers and copolymers of acrylic acid, methacrylic acid, and other derivatives of acrylic acid, polymers with pendant SO 3 H groups such as sulfonated polystyrene, and polystyrene with carboxylic acid groups.
  • the present invention provides methods identifying new and useful inhibitors of Cathepsin K for use in stimulating bone production.
  • These assays may comprise random screening of large libraries of candidate substances; alternatively, the assays may be used to focus on particular classes of compounds selected with an eye towards structural attributes that are believed to make them more likely to modulate the function of Cathepsin K.
  • a method generally comprises:
  • step (c) measuring Cathepsin K activity or expression or bone formation; and (d) comparing the characteristic measured in step (c) with that observed in the absence of the candidate modulator, wherein a difference between the measured characteristic indicates that said candidate modulator is, indeed, a modulator of Cathepsin K.
  • Assays may be conducted in cell free systems, in isolated cells, or in organisms including transgenic animals. Bone formation can be identified by the von Koassa or Alzarin Red stains, FTIR or Raman spectrometric analysis, or by fluorochromes linked to compounds that bind bone.
  • U.S. Patent 6,346,373 describes a whole cell based assay for Cathepsin K activity. It will, of course, be understood that all the screening methods of the present invention are useful in themselves notwithstanding the fact that effective candidates may not be found. The invention provides methods for screening for such candidates, not solely methods of finding them.
  • Cathepsin K inhibition simulates ex vivo bone formation
  • Velcura's proprietary technology covering human growth in tissue culture (ex vivo bone formation) results in the formation of three-dimensional tissue like aggregates, the up-regulation of bone proteins such as osteonectin and alkaline phosphatase and the formation of human bone (Kale et al., 2000).
  • This core technology provides the ability to rapidly grow human bone in tissue culture. As shown in FIG.
  • osteoblasts human bone cells
  • an osteogenic compound small molecule or biological
  • the osteoblasts then produce monophosphate- and carbonate derivatized hydroxyapatite analogous to human bone, as demonstrated via FTIR and Ramen spectrometry (Kale et al., 2000).
  • This bone-formation is detected in a variety of ways; for example, visualization of the calcium in the bone with a fluorescent probe (FIG. 2, arrows).
  • FOG. 2, arrows fluorescent probe
  • Patents 5,843,992; 6,387,908; 6,689,785 provide for intracellular inhibition.
  • a lead compound, VEL-0230 is an orally available Cathepsin K inhibitor that stimulates ex vivo bone formation (FIG. 2) and both promotes bone formation and prevents bone loss in animal models (see below). Additionally, the inventor has used our ex vivo bone formation technologies to develop other compounds with similar properties to VEL-0230 to investigate as second generation compounds.
  • the inventor statistically evaluated Lysate assay IC 50 values for VEL-0230 and the other NC-related compounds, determining the mean as well as the 95% and 99% confidence intervals around these means (Table 1). From this, compounds having an IC 50 similar to VEL-0230 were defined as those with a similar shaped concentration response profile as well as an IC 5O value that was within the 95% Confidence Interval for this group, i.e., within an IC 50 range of 297.8-350.4 nM (FIG. 3 & Table 1).
  • osteoblasts were mock transfected in the absence of siRNA (Control) to determine the effects of transfection; (2) non-functional siRNAs that minimally interact with the RISC complex (Non- RISC) were introduced to determine the potential off-target affects of transfection; and (3) non- targeting siRNAs that interact with RISC but are bioinformatically designed to minimize possible interaction with human cellular RNA (non-targeting) were used to measure the effect of RISC activation by siRNAs. None of these controls significantly altered Cathepsin K expression or osteoblast phenotype. However, siRNAs targeting Cathepsin K significantly reduce Cathepsin K mRNA levels in human osteoblasts as compared to controls (FIG.
  • the inventor also investigated an osteoporosis prevention model in chronically-treated Cynomolgus monkeys: sham-operated (Sham), ovariectomized (OVX) and OVX VEL-0230-treated animals are evaluated.
  • the VEL-0230 biomarker and density data support an anabolic effect of VEL-0230 treatment. Biochemical markers of both bone formation are significantly elevated in treated animals and resorption markers are significantly decreased (bone resorption markers not shown).
  • VEL-0230 treated OVX animals show marked increases in the bone formation markers osteocalcin (FIG. 8A, OC; 400% to 800%) and in bone-specific alkaline phosphatase (FIG. 8B, BSAP; 40%-60%).
  • OVX animals The increase in OVX animals is expected, as it is being driven by the increased resorption (increased OC in Sham animals remains unexplained).
  • the OVX animals show significant reductions in bone mineral density (BMD) whereas the Sham treated animals show no significant changes.
  • BMD bone mineral density
  • VEL-0230 treated animals show a later but marked, albeit not yet significant, increase in BMD the higher dose treatment group and a modest increase in BMD in the low dose animals in weeks 16-32 (FIG. 8C).
  • Raw gene chip data was imported into the Gene Spring software package (www.silicongenet-ics.com) for statistical analysis. Data transformation was performed with values less than 0.01 set to 0.01. To control for chip-wide variation in staining intensity, per chip normalization was performed with all measurements on the chip divided by the 50% percentile value. To account for differences in detection efficiency between probe sets, signal intensity for each probe set in the sample was divided by the median signal intensity for that probe set in the experimental group. Genes that vary significantly across the data set were identified using a paired t-test.
  • TGF- ⁇ l a powerful and pleiotropic growth factor, induces ex vivo bone formation has features in common with other members of the TFG- ⁇ super-family; however, other osteogenic growth factors do display distinct expression implying both factor-specific and common pathway genes can (eventually) be identified.
  • FIG. 10 This data set represents 8600 differentially regulated genes. To more precisely define the set of responding genes further selection criteria were applied.
  • each induction group was analyzed individually with Affymetrix HU133 chip sets (resulting in 6 data sets: IGF-I, PTH, Vitamin D3, and TGF- ⁇ Days 1, 3, and 5).
  • Affymetrix HU133 chip sets resulting in 6 data sets: IGF-I, PTH, Vitamin D3, and TGF- ⁇ Days 1, 3, and 5.
  • a probe set had to have a two-tailed p-vahie less than or equal to 0.05 from the paired t-test. hi addition, the probe set had to:
  • the net result of using the OsteoChipTM is the reduction of the analyzed gene pool from the 20,000 or 30,000 genes in the human genome to 1281. This greatly enhances the rapidity with which one can analyze anabolic compounds. Nonetheless, examination of this reduced number of genes is meaningless unless they are put into a context of cellular signaling pathways.
  • the inventor utilizes pathway analysis programs to identify both novel path-ways (not shown) and canonical pathways that are activated during ex vivo bone formation (FIG. 12).
  • RNA interference RNA interference
  • compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims. VIII. References

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

The invention regards the modulation of a proteolytic enzyme, Cathepsin K that results in increased bone production by bone-forming cells. Drugs that target this enzyme within bone forming cells and inhibit its activity represent a new class of anabolic, or bone building, therapies. Such drugs are useful in the treatment of diseases or disorders such as osteoporosis, Paget' s disease, metastatic bone cancer, bone fractures, etc.

Description

DESCRIPTION
USE OF CATHEPSIN K ANTAGONISTS IN BONE PRODUCTION
BACKGROUND OF THE INVENTION
The present invention claims priority to U.S. Provisional Application Serial
Nos. 60/747,886 and 60/810,456, filed May 22, 2006 and June 1, 2006, respectively, the entire contents of which are hereby incorporated by reference.
I. Field of the Invention The present invention relates to the fields of molecular biology and medicine.
More particularly, it relates to the fields of bone disease & injury, bone repair,, bone implants, bone grafts and periodontal disease. Specifically, it deals with the use of Cathepsin K antagonists to promote bone formation.
II. Related Art Over 200 million people worldwide suffer from bone disorders such as osteoporosis, bone fractures, and periodontal (gum) disease (where the teeth loose surrounding bone). Osteoporosis represents a large and rapidly growing health care problem with an unmet medical need for therapies that stimulate bone formation. Most current drugs for osteoporosis retard bone degradation but do not stimulate bone formation to replace already lost bone. Compounds that stimulate bone formation thus represent an unmet need in the area of bone disease. Osteoporosis is known to affect approximately 100 million people worldwide - 35 million of whom live in the U.S., Western Europe and Japan. Moreover, over 25 million individuals suffer bone fractures yearly, 60 million have periodontal disease (in which the tooth loosens from the jaw bone), and another 18 million have other bone disorders such as bone cancer.
Most current therapies for osteoporosis patients focus on prevention of bone loss, not bone formation . This remains an important consideration as significant morbidity and mortality are associated with prolonged bed rest in the elderly, particularly those who have suffered hip fractures. Complications of bed rest include blood clots and pneumonia. These complications are recognized and measures are usually taken to avoid them, but these is hardly the best approach to therapy.
Yet another bone-related health issues is bone reconstruction and, specifically, the ability to reconstruct defects in bone tissue that result from traumatic injury, as a consequence of cancer or cancer surgery, as a result of a birth defect, or as a result of aging. There is a significant need for more frequent orthopedic implants, and cranial and facial bone are particular targets for this type of reconstructive need. The availability of new implant materials, e.g., titanium, has permitted the repair of relatively large defects. Titanium implants provide excellent temporary stability across bony defects. However, experience has shown that a lack of viable bone bridging the defect can result in exposure of the appliance, infection, structural instability and, ultimately, failure to repair the defect.
Autologous bone grafts are another possibility to deal with bone injury, but they have several demonstrated disadvantages in that they must be harvested from a donor site such as iliac crest or rib, they usually provide insufficient bone to completely fill the defect, and the bone that does form is sometimes prone to infection and resorption. Partially purified xenogeneic preparations are not practical for clinical use because microgram quantities are purified from kilograms of bovine bone, making large scale commercial production both costly and impractical. Allografts and demineralized bone preparations are therefore often employed. Microsurgical transfers of free bone grafts with attached soft tissue and blood vessels can close bony defects with an immediate source of blood supply to the graft. However, these techniques are time consuming, have been shown to produce a great deal of morbidity, and can only be used by specially trained individuals. Therefore, there continues to be a need for improved methods of stimulating bone formation in vivo to treat bone disease and injury, and for producing bone ex vivo in the production and use of implants. SUMMARY OF THE INVENTION
Thus, in accordance with the present invention, there is provided a method of promoting bone formation comprising (i) selecting a first intracellular Cathepsin K inhibitor; and (ii) administering to a subject the first inhibitor of Cathepsin K. The inhibitor may be a biological or an organopharmaceutical small molecule. The biological may be a peptide, an siRNA, an antisense molecule or a single-chain antibody. The organopharmaceutical small molecule may be a structural variant of a known Cathepsin K inhibitor based on hydrophilic and lipophilic characteristics, spatial properties, or other information available from medicinal chemistry and chemical enzymology studies on these compounds. The organopharmaceutical may be an epoxysuccinamide, VEL-0230 or analog thereof. The first inhibitor may also prevent bone resorption. The subject may suffer from a bone-related pathology or injury, such as osteoporosis, vitamin D deficiency, bone cancer, bone fracture, periodontal disease, Paget' s disease, osteoporosis secondary to other diseases, or in need of bone grafts or implants. The subject is a human or a non-human animal. The compound may possess or lack bone resorption inhibition.
The method may further comprise contacting the subject with a second agent. The second agent may be a bisphosphonate, a PTH analog, or a second inhibitor of Cathepsin K that is distinct from the first inhibitor. The second inhibitor of Cathepsin K may be an extracellular inhibitor of Cathepsin K. The first and/or second inhibitor may be formulated to increase transmembrane delivery. The first and/or second inhibitor may be formulated with a cell permeability factor. The first and/or second inhibitor may be formulated in a lipid delivery vehicle. The first and/or second inhibitor may be formulated to enhance its bioavailability. The first and/or second inhibitor may be administered to the subject more than once. The first and/or second inhibitor is administered to the subject by oral or intravenous routes.
In another embodiment, there is provided a method of producing bone from an isolated bone cell comprising (i) selecting an intracellular Cathepsin K inhibitor; (ii) contacting the bone cell with the inhibitor of Cathepsin K; and (iii) culturing the cell under conditions promoting bone formation. The method may further comprise implanting the bone cell or bone derived therefrom in a subject. The bone cell may have been obtained, prior to step (ii) from the subject. The obtained cell may have been derived from a stem cell prior to step (ii). The stem cell may have been under conditions promoting the formation of an osteogenic cell prior to step (ii). The compound may possess or lack bone resorption inhibition.
In still another embodiment, there is provided a method of identifying an agent that promotes bone formation comprising (i) providing a candidate compound; (ii) admixing the candidate compound with an isolated Cathepsin K enzyme, or a cell expressing Cathepsin K, or an experimental animal, cells of which express Cathepsin
K; (iii) measuring Cathepsin K activity or expression or bone formation; and (iv) comparing the characteristic measured in step (iii) with that observed in the absence of the candidate modulator, wherein a difference between the measured characteristic indicates that the candidate compound is, indeed, a modulator of Cathepsin K. The compound may possess or lack bone resorption inhibition.
It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein.
The use of the word "a" or "an" when used in conjunction with the term "comprising" in the claims and/or the specification may mean "one," but it is also consistent with the meaning of "one or more," "at least one," and "one or more than one."
It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method or composition of the invention, and vice versa. Furthermore, compositions and kits of the invention can be used to achieve methods of the invention.
Throughout this application, the term "about" is used to indicate that a value includes the inherent variation of error for the device, the method being employed to determine the value, or the variation that exists among the study subjects.
BRIEF DESCRIPTION OF THE DRAWINGS
The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.
FIG. 1 - Ex vivo Bone Formation. A 3 -dimensional tissue like aggregate of human osteoblasts (red) and bone collagen (blue). Masson Stain.
FIG. 2 - Bone formation. Bone forming in tissue like aggregates of human osteoblasts is indicated by Ca2+ fluorescence (arrows).
FIG. 3 - IC_sn Values for VEL-0230 and Related Compounds in Cell Lysates. See Text. N.B. VEL-0230 is labeled as NC-2300 in this figure.
FIG. 4 - Cell Lvsate versus Intact Cell IC50 Determinations for VEL-0230.
FIG. 5 - Reduction of Cathepsin K mRNA by siRNAs.
FIG. 6 - Reduction of Cathepsin K mRNA by siRNAs.
FIG. 7 - VEL-0230 Prevents Trabecular Bone Loss. N.B. Center panel is not "washed out", but lacks bone that is red in this histochemical stain.
FIG. 8 - VEL-0230 Prevents Cortical Bone Loss.
FIG. 9 - Osteocalcin. BSAP & BMP Levels in VEL-0230-treated Primates.
FIG. 10 - Non-supervised Hierarchical Clustering of Gene Expression
Changes Following OsteoRenic Growth Factor Induction. See text. Red = Down regulated; blue = up regulated.
FIG. 11 - Families of Genes Involved in Ex vivo Bone Formation.
FIG. 12 - TGF-β Induced Osteoblast Signaling Pathway. Green circles = Up regulated gene; red = down regulated; GeneGo Map. DETAILED DESCRIPTION OF THE INVENTION
The inventor has demonstrated bone formation in tissue culture using methodology described in U.S. Patent 6,811,786, included herein by reference. Using this system, he has discovered a unique mechanism of action for Cathepsin K, a proteolytic enzyme previously thought to be involved only in bone degradation. Its role in modulating bone resorption is that of a classic proteolytic enzyme, functioning to degrade components of the extra-cellular compartment, particularly collagen (Bossard et al, 1996). Moreover, the prevalent viewpoint is that this enzyme functions solely and/or selectively in osteoclasts to degrade extracellular proteins and, as such, is targeted by anti-catabolic therapies that function to inhibit the bone- resorbing osteoclast (Yasuda et al, 2005; Grabowskal et al, 2005; Troen, 2004; Dodds, 2003; Zaidi et al, 2003). Recently, Cathepsin K was shown to be expressed by osteoblasts; however, this report still subscribed to the concept that Cathepsin K has an extracellular role and, further, did not test enzymatic function of this enzyme within osteoblasts (Mandelin et al, 2006).
An important feature of the present invention is that within bone-forming cells Cathepsin K plays a role in bone formation as inhibition of the enzyme unexpectedly results in an increase in bone formation, as described below. The role of Cathepsin K in bone formation intracellular signaling networks is supported by three observations: (1) the inventor's Cathepsin K inhibitors stimulate bone formation both in vivo and in vitro, (2) RNA interference studies of Cathepsin K (RNAi; performed via small- interfering RNA (siRNA) treatment) demonstrate that inhibition of this message results in a bone-formation phenotype in treated human osteoblasts, and (3) stimulation of bone formation with multiple osteogenic growth factors decreases Cathepsin K message and activity within the osteoblast.
Numerous patents exist on the structure of Cathepsin K inhibitors and their use in treating the extracellular activity of the enzyme. PCT application WO 2005/049028 Al describes the use of Cathepsin K inhibitors to stimulate bone formation in a patient in need of such a treatment. However, the data therein does not demonstrate this effect in humans, nor do two related abstracts. Moreover, these references disclose and advocate the use of inhibitors in line with the conventional viewpoint of extracellular inhibition of osteoclast Cathepsin K. The present invention, by way of contrast, proposes the use of intracellular inhibition of Cathepsin K in both in vivo and ex vivo contexts.
I. Cathepsin K Cathepsins are proteases that function in the normal physiological as well as pathological degradation of connective tissue. Cathepsins play a major role in intracellular protein degradation and turnover, bone remodeling, and prohormone activation (Marx, 1987). Cathepsin B, H, L and S are ubiquitously expressed lysosomal cysteine proteinases that belong to the papain superfamily. They are found at constitutive levels in many tissues in the human including kidney, liver, lung and spleen. Some pathological roles of cathepsins include an involvement in glomerulonephritis, arthritis, and cancer metastasis (Sloan and Honn, 1984). Greatly elevated levels of cathepsin L and B mRNA and protein are seen in tumor cells. Cathepsin L mRNA is also induced in fibroblasts treated with tumor promoting agents and growth factors (Kane and Gottesman, 1990).
Cathepsin K, a member of this protease family, is considered the primary protease responsible for the degradation of the bone matrix. Cathepsin K was discovered in 1994, is synthesized as a 37 kDa pre-pro enzyme, and is presumably autoactivated to the mature 27 kDa enzyme at low pH (McQueney et ah, 1997; Littlewood-Evans et al, 1997; U.S. Patent 5,861,298). It is abundantly and relatively selectively expressed in osteoclasts, where it is localized in lysosomes in the ruffled border and in resorption lacunae on the bone surface. This cellular and extracellular localization suggests an important role in bone resorption, as does its recently characterized functional activity profile. The unique ability of Cathepsin K to degrade type I collagen both within and outside the helical regions and also type II collagens at the N-terminal of the triple helix, to act at an acidic and neutral pH, shows that Cathepsin K plays an important role in bone and cartilage break down.
II. Bone Therapy Using Cathepsin K Antagonists A. Antagonists
The U.S. Patents 5,843,992, 6,387,908 and 6,689,785, incorporated by reference, are drawn to the structures underlying VEL-0230 and its analogues as Cathepsin K inhibitors and their use in osteoporosis, malignant hypercalcemia, Paget' s Disease, and arthritis. The only known activity of Cathepsin K antagonists is to modulate the extracellular activity of Cathepsin K. An agent of the present invention is one that is capable of inhibiting the extracellular function of Cathepsin K and also promoting the formation of bone in vitro and/or in vivo by the inhibition of intracellular Cathepsin K within the osteoclast. The agent may also inhibit bone resorption. The effect of these molecular and cellular actions will be to treat bone disease and injury and to improve the function in the clinical situation (reduction in pain, increase in mobility, etc.) of a subject suffering from bone-related pathologies.
Other agents may be used in combination with intracellular Cathepsin K inhibitors. More generally, these agents would be provided in a combined amount (along with the intracellular inhibitor) to produce any of the effects discussed above. This process may involve contacting the cell or subject with both agents at the same time. This may be achieved by contacting the cell with a single composition or pharmacological formulation that includes both agents, or by contacting the cell or subject with two distinct compositions or formulations, at the same time, wherein one composition includes the intracellular inhibitor and the other includes the second agent.
Alternatively, one agent may precede or follow the other by intervals ranging from minutes to weeks. In embodiments where the agents are applied separately to the cell or subject, one would generally ensure that a significant period of time did not expire between the time of each delivery, such that the agents would still be able to exert an advantageously combined effect on the cell or subject. In such instances, it is contemplated that one may contact the cell with both modalities within about 12-24 h of each other and, more preferably, within about 6-12 h of each other. In some situations, it may be desirable to extend the time period for treatment significantly, however, where several days (2, 3, 4, 5, 6 or 7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between the respective administrations.
Various combinations may be employed, the intracellular inhibitor of Cathepsin K is "A" and the other agent is "B":
A/B/A B/A/B B/B/A PJPJB PJBIB BIPJK AJBIBIB BIAJBIB
B/B/B/A B/B/A/B PJPJBIB PJBIPJB PJBfBIA BIBIAIA BIAJBIA BIAIAJB PJPJPJB BIPJPJA AJBIAJA AJAJBIA Administration protocols and formulation of such agents will generally follow those of standard pharmaceutical drugs, as discussed further below. Combination agents include bisphosphonates (Didronel™, Fosamax™ and Actonel™), SERMs (Evista) or other hormone derivatives, and Parathyroid Hormone (PTH) analogs. In addition, U.S. Patents 6,642,239, 6,531,612, 6,462,076 and 6,274,336, as well as U.S. Publication Nos. 2006/0074092, 2006/0020001, 2005/0245596, 2005/0107616, 2005/0054819, and 2004/0249153, disclose other Cathepsin K inhibitors that work in an extracellular fashion.
B. Diseases and Conditions Requiring Bone Repair
The following is a brief discussion of human conditions that exemplify the variety of diseases and disorders that would benefit from the use of Cathepsin K antagonists or cells treated therewith in promoting bone formation and/or bone repair. In addition to the following, several other conditions, such as, for example, vitamin D deficiency, exists.
Fracture. The first example is the otherwise healthy individual who suffers a fracture. Often, clinical bone fracture is treated by casting to alleviate pain and allow natural repair mechanisms to repair the wound. There has been progress in the treatment of fracture in recent times, however, even without considering the various complications that may arise in treating fractured bones, any new procedures to increase bone healing in normal circumstances would represent a great advance.
Periodontal Disease. Progressive periodontal disease leads to tooth loss through destruction of the tooth's attachment to the surrounding bone. Approximately 5 - 20% of the U.S. population (15-60 million individuals) suffers from severe generalized periodontal disease, and there are 2 million related surgical procedures. Moreover, if the disease is defined as the identification of at least one site of clinical attachment loss, then approximately 80% of all adults are affected, and 90% of those aged 55 to 64 years. If untreated, approximately 88% of affected individuals show moderate to rapid progression of the disease' which shows a strong correlation with age. The major current treatment for periodontal disease is regenerative therapy consisting of replacement of lost periodontal tissues. The lost bone is usually treated with an individual's own bone and bone marrow, due to their high osteogenic potential. Bone allografts (between individuals) can also be performed using stored human bone. Although current periodontal cost analyses are hard to obtain, the size of the affected population and the current use of bone grafts as a first-order therapy strongly suggest that this area represents an attractive target for bone-building therapies.
Osteopenia/osteoporosis. The terms osteopenia and osteoporosis refers to a heterogeneous group of disorders characterized by decreased bone mass and fractures. Osteopenia is a bone mass that is one or more standard deviations below the mean bone mass for a population; osteoporosis is defined as 2.5 SD or lower. An estimated 20-25 million people are at increased risk for fracture because of site-specific bone loss. Risk factors for osteoporosis include increasing age, gender (more females), low bone mass, early menopause, race (Caucasians in general; asian and hispanic females), low calcium intake, reduced physical activity, genetic factors, environmental factors (including cigarette smoking and abuse of alcohol or caffeine), and deficiencies in neuromuscular control that create a propensity to fall.
More than a million fractures in the USA each year can be attributed to osteoporosis. In economic terms, the costs (exclusive of lost wages) for osteoporosis therapies are $35 billion worldwide. Demographic trends (i.e., the gradually increasing age of the US population) suggest that these costs may increase to $62 billion by the year 2020. Clearly, osteoporosis is a significant health care problem.
Osteoporosis, once thought to be a natural part of aging among women, is no longer considered age or gender-dependent. Osteoporosis is defined as a skeletal disorder characterized by compromised bone strength predisposing to an increased risk of fracture. Bone strength reflects the integration of two main features: bone density and bone quality. Bone density is expressed as grams of mineral per area or volume and in any given individual is determined by peak bone mass and amount of bone loss. Bone quality refers to architecture, turnover, damage accumulation (e.g., microfractures) and mineralization. A fracture occurs when a failure-inducing force (e.g. , trauma) is applied to osteoporotic bone.
Current therapies for osteoporosis patients focus on fracture prevention, not fracture repair. This remains an important consideration because of the literature, which clearly states that significant morbidity and mortality are associated with prolonged bed rest in the elderly, particularly those who have suffered hip fractures. Complications of bed rest include blood clots and pneumonia. These complications are recognized and measures are usually taken to avoid them, but these is hardly the best approach to therapy. Thus, the osteoporotic patient population would benefit from new therapies designed to strengthen bone and speed up the fracture repair process, thus getting these people on their feet before the complications arise.
Bone Reconstruction/Grafting. A fourth example is related to bone reconstruction and, specifically, the ability to reconstruct defects in bone tissue that result from traumatic injury; as a consequence of cancer or cancer surgery; as a result of a birth defect; or as a result of aging. There is a significant need for more frequent orthopedic implants, and cranial and facial bone are particular targets for this type of reconstructive need. The availability of new implant materials, e.g., titanium, has permitted the repair of relatively large defects. Titanium implants provide excellent temporary stability across bony defects. However, experience has shown that a lack of viable bone bridging the defect can result in exposure of the appliance to infection, structural instability and, ultimately, failure to repair the defect. Thus, a therapeutic agent that stimulates bone formation on or around the implant will facilitate more rapid recovery. Autologous bone grafts are another possibility, but they have several demonstrated disadvantages in that they must be harvested from a donor site such as iliac crest or rib, they usually provide insufficient bone to completely fill the defect, and the bone that does form is sometimes prone to infection and resorption. Partially purified xenogeneic preparations are not practical for clinical use because microgram quantities are purified from kilograms of bovine bone, making large scale commercial production both costly and impractical. Allografts and demineralized bone preparations are therefore often employed.
Microsurgical transfers of free bone grafts with attached soft tissue and blood vessels can close bony defects with an immediate source of blood supply to the graft. However, these techniques are time consuming, have been shown to produce a great deal of morbidity, and can only be used by specially trained individuals. Furthermore, the bone implant is often limited in quantity and is not readily contoured. In the mandible, for example, the majority of patients cannot wear dental appliances using presently accepted techniques (even after continuity is established), and thus gain little improvement in the ability to masticate.
In connection with bone reconstruction, specific problem areas for improvement are those concerned with treating large defects, such as created by trauma, birth defects, or particularly, following tumor resection; and also the area of artificial joints. The success of orthopaedic implants, interfaces and artificial joints could conceivably be improved if the surface of the implant, or a functional part of an implant, were to be coated with a bone stimulatory agent. The surface of implants could be coated with one or more appropriate materials in order to promote a more effective interaction with the biological site surrounding the implant and, ideally, to promote tissue repair.
III. Pharmaceutical Formulations and Delivery A. Compositions and Routes
Pharmaceutical compositions of the present invention comprise an effective amount of one or more Cathepsin K antagonists dissolved or dispersed in a pharmaceutically acceptable carrier. The phrases "pharmaceutical or pharmacologically acceptable" refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate. The preparation of a pharmaceutical composition that contains at least one Cathepsin K antagonist, and optionally an additional active ingredient, will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, incorporated herein by reference. Moreover, for animal (e.g., human) administration, it will be understood that preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biological Standards.
As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329, incorporated herein by reference). Except insofar as any conventional carrier is incompatible with the active ingredient, its use in the pharmaceutical compositions is contemplated.
The Cathepsin K antagonist may be admixed with different types of carriers depending on whether it is to be administered orally or by injection. The present invention can be administered buccally, intravenously, intradermally, transdermally, intrathecally, intraarterially, intraperitoneally, intranasally, intravaginally, intrarectally, topically, intramuscularly, subcutaneously, mucosally, orally, topically, locally, inhalation (e.g., aerosol inhalation), injection, infusion, continuous infusion, localized perfusion bathing target cells directly, via a catheter, via a lavage, in cremes, in lipid compositions (e.g., nanoparticles, liposomes), or by other method or any combination of the forgoing as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, incorporated herein by reference).
The Cathepsin K antagonist may be formulated into a composition in a free base, neutral or salt form. Pharmaceutically acceptable salts, include the acid addition salts, e.g., those formed with the free amino groups of a proteinaceous composition, or which are formed with inorganic acids such as for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, fumaric, or mandelic acid. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as for example, sodium, potassium, ammonium, calcium or ferric hydroxides; or such organic bases as isopropylamine, trimethylamine, histidine or procaine. Upon formulation, solutions will be administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective.
Further in accordance with the present invention, the composition of the present invention suitable for administration is provided in a pharmaceutically acceptable carrier with or without an inert diluent. The carrier should be assimilable and includes liquid, semi-solid, i.e., pastes, or solid carriers. Except insofar as any conventional media, agent, diluent or carrier is detrimental to the recipient or to the therapeutic effectiveness of the composition contained therein, its use in administrable composition for use in practicing the methods of the present invention is appropriate. Examples of carriers or diluents include fats, oils, water, saline solutions, lipids, liposomes, resins, binders, fillers and the like, or combinations thereof. The composition may also comprise various antioxidants to retard oxidation of one or more component. Additionally, the prevention of the action of microorganisms can be brought about by preservatives such as various antibacterial and antifungal agents, including but not limited to parabens (e.g., methylparabens, propylparabens), chlorobutanol, phenol, sorbic acid, thimerosal or combinations thereof.
In a specific embodiment of the present invention, the composition is combined or mixed thoroughly with a semi-solid or solid carrier. The mixing can be carried out in any convenient manner such as grinding. Stabilizing agents can be also added in the mixing process in order to protect the composition from loss of therapeutic activity, i.e., denaturation in the stomach. Examples of stabilizers for use in an the composition include buffers, amino acids such as glycine and lysine, carbohydrates such as dextrose, mannose, galactose, fructose, lactose, sucrose, maltose, sorbitol, mannitol, etc.
In further embodiments, the present invention may concern the use of a pharmaceutical lipid vehicle compositions that include Cathepsin K antagonist, one or more lipids, and an aqueous solvent. As used herein, the term "lipid" will be defined to include any of a broad range of substances that is characteristically insoluble in water and extractable with an organic solvent. This broad class of compounds are well known to those of skill in the art, and as the term "lipid" is used herein, it is not limited to any particular structure. Examples include compounds which contain long- chain aliphatic hydrocarbons and their derivatives. A lipid may be naturally- occurring or synthetic (i.e., designed or produced by man). Lipids are well known in the art, and include for example, neutral fats, phospholipids, phosphoglycerides, steroids, terpenes, lysolipids, glycosphingolipids, glycolipids, sulphatides, lipids with ether and ester-linked fatty acids and polymerizable lipids, and combinations thereof.
One of ordinary skill in the art would be familiar with the range of techniques that can be employed for dispersing a composition in a lipid vehicle. For example, the Cathepsin K antagonist may be dispersed in a solution containing a lipid, dissolved with a lipid, emulsified with a lipid, mixed with a lipid, combined with a lipid, covalently bonded to a lipid, contained as a suspension in a lipid, contained or complexed with a micelle or liposome, or otherwise associated with a lipid or lipid structure by any means known to those of ordinary skill in the art. The dispersion may or may not result in the formation of liposomes.
The actual dosage amount of a composition of the present invention administered to an animal patient can be determined by physical and physiological factors such as body weight, severity of condition, the type of disease being treated, previous or concurrent therapeutic interventions, idiopathy of the patient and on the route of administration. Depending upon the dosage and the route of administration, the number of administrations of a preferred dosage and/or an effective amount may vary according to the response of the subject. The practitioner responsible for administration will, in any event, determine the concentration of active ingredient(s) in a composition and appropriate dose(s) for the individual subject.
In certain embodiments, Cathepsin K antagonist pharmaceutical compositions may comprise, for example, at least about 0.1% of the antagonist, about 0.5% of the antagonist, or about 1.0% of the antagonist, hi other embodiments, the antagonist may comprise between about 2% to about 75% of the weight of the unit, or between about 25% to about 60%, for example, and any range derivable therein. Naturally, the amount of the antagonist in each therapeutically useful composition may be prepared is such a way that a suitable dosage will be obtained in any given unit dose of the compound. Factors such as solubility, bioavailability, biological half-life, route of administration, product shelf life, as well as other pharmacological considerations will be contemplated by one skilled in the art of preparing such pharmaceutical formulations, and as such, a variety of dosages and treatment regimens may be desirable. hi other non- limiting examples, a dose of a Cathepsin K antagonist may also comprise from about 0.1 microgram/kg/body weight, about 0.2 microgram/kg/body weight, about 0.5 microgram/kg/body weight, about 1 microgram/kg/body weight, about 5 microgram/kg/body weight, about 10 microgram/kg/body weight, about 50 microgram/kg/body weight, about 100 microgram/kg/body weight, about 200 microgram/kg/body weight, about 350 microgram/kg/body weight, about 500 microgram/kg/body weight, about 1 milligram/kg/body weight, about 5 milligram/kg/body weight, about 10 milligram/kg/body weight, about 50 milligram/kg/body weight, about 100 milligram/kg/body weight, about 200 milligram/kg/body weight, about 350 milligram/kg/body weight, about 500 milligram/kg/body weight, to about 1000 mg/kg/body weight or more per administration, and any range derivable therein, hi non-limiting examples of a derivable range from the numbers listed herein, a range of about 5 mg/kg/body weight to about 100 mg/kg/body weight, about 5 microgram/kg/body weight to about 500 milligram/kg/body weight, etc., can be administered, based on the numbers described above. hi particular embodiments of the present invention, the Cathepsin K antagonists are formulated to be administered via an alimentary route. Alimentary routes include all possible routes of administration in which the composition is in direct contact with the alimentary tract. Specifically, the pharmaceutical compositions disclosed herein may be administered orally, buccally, rectally, or sublingually. As such, these compositions may be formulated with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard- or soft- shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.
In certain embodiments, the active compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like (Mathiowitz et al., 1997; Hwang et al, 1998; U.S. Patents 5,641,515, 5,580,579 and 5,792, 451, each specifically incorporated herein by reference in its entirety). The tablets, troches, pills, capsules and the like may also contain the following: a binder, such as, for example, gum tragacanth, acacia, cornstarch, gelatin or combinations thereof; an excipient, such as, for example, dicalcium phosphate, mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate or combinations thereof; a disintegrating agent, such as, for example, corn starch, potato starch, alginic acid or combinations thereof; a lubricant, such as, for example, magnesium stearate; a sweetening agent, such as, for example, sucrose, lactose, saccharin or combinations thereof; a flavoring agent, such as, for example peppermint, oil of wintergreen, cherry flavoring, orange flavoring, etc. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules may be coated with shellac, sugar, or both. When the dosage form is a capsule, it may contain, in addition to materials of the above type, carriers such as a liquid carrier. Gelatin capsules, tablets, or pills may be enterically coated. Enteric coatings prevent denaturation of the composition in the stomach or upper bowel where the pH is acidic. See, e.g., U.S. Patent 5,629,001. Upon reaching the small intestines, the basic pH therein dissolves the coating and permits the composition to be released and absorbed by specialized cells, e.g., epithelial enterocytes and Peyer's patch M cells. A syrup of elixir may contain the active compound sucrose as a sweetening agent methyl and propylparabens as preservatives, a dye and flavoring, such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the active compounds may be incorporated into sustained-release preparation and formulations. For oral administration, such as in the treatment of periodontal disease, the compositions of the present invention may alternatively be incorporated with one or more excipients in the form of a mouthwash, dentifrice, buccal tablet, oral spray, gel or sublingual orally-administered formulation. For example, a mouthwash may be prepared incorporating the active ingredient in the required amount in an appropriate solvent, such as a sodium borate solution (Dobell's Solution). Alternatively, the active ingredient may be incorporated into an oral solution such as one containing sodium borate, glycerin and potassium bicarbonate, or dispersed in a dentifrice, or added in a therapeutically-effective amount to a composition that may include water, binders, abrasives, flavoring agents, foaming agents, and humectants. Alternatively the compositions may be fashioned into a tablet, gel or solution form that may be placed under the tongue, along the gum line, brushed on to teeth surfaces, or otherwise dissolved in the mouth. U.S. Patents 6,074,674 and 6,270,750, both incorporated by reference, describe topical, sustained release compositions for periodontal procedures .
In further embodiments, Cathepsin K antagonist may be administered via a parenteral route. As used herein, the term "parenteral" includes routes that bypass the alimentary tract. Specifically, the pharmaceutical compositions disclosed herein may be administered for example, but not limited to intravenously, intradermally, intramuscularly, intraarterially, intrathecally, subcutaneous, or U.S. Patents 6,537,514, 6,613,308, 5,466,468, 5,543,158; 5,641,515; and 5,399,363 (each specifically incorporated herein by reference in its entirety). Solutions of the active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (U.S. Patent 5,466,468, specifically incorporated herein by reference in its entirety), hi all cases the form must be sterile and must be fluid to the extent that easy injectability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (i.e., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, and intraperitoneal administration. In this connection, sterile aqueous media that can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, "Remington's Pharmaceutical Sciences" 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologies standards.
Sustained release formulations for treating of bone conditions include U.S. Patents 4,722,948, 4,843,112, 4,975,526, 5,085,861, 5,162,114, 5,741,796 and 6,936,270, all of which are incorporated by reference. Methods and injectable compositions for bone repair are described in U.S. Patents 4,863,732, 5,531,791, 5,840,290, 6,281,195, 6,288,043, 6,485,754, 6,662,805 and 7,008,433, all of which are incorporated by reference.
Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile- filtered solution thereof. A powdered composition is combined with a liquid carrier such as, e.g., water or a saline solution, with or without a stabilizing agent.
B. Devices hi addition to provide Cathepsin K inhibitors and pharmaceuticals for administration by routes discussed above, such inhibitors maybe used in the context of devices, such as implants. A variety of bone related implants are contemplated, including dental implants, joint implants such as hips, knees, and elbows, vertebral/spinal implants, and others. The Cathepsin K inhibitor may be impregnated in a surface of the implant, including in a bioactive matrix or coating. The inhibitor may further formulated to sustained, delayed, prolonged or time release. The coating may comprise polymers, for example, such as those listed below in Section V. The following is a list of U.S. Patents relating to bone implants and devices which may be utilized in accordance with this embodiment of the invention:
TABLE 1 -BONE IMPLANT PATENTS
U.S. Patent* Patent Title
7,044,972 Bone implant, in particular, an inter-vertebral implant
7,022,137 Bone hemi-lumbar interbody spinal fusion implant having an asymmetrical leading end and method of installation thereof
7,001,551 Method of forming a composite bone material implant
6,994,726 Dual function prosthetic bone implant and method for preparing the same
6,989,031 Hemi-interbody spinal implant manufactured from a major long bone ring or a bone composite
6,988,015 Bone implant
6,981,975 Method for inserting a spinal fusion implant having deployable bone engaging projections
6,981,872 Bone implant method of implanting, and kit for use in making implants, particularly useful with respect to dental implants 6,929,662 End member for a bone fusion implant
6,923,830 Spinal fusion implant having deployable bone engaging projections
6,921,264 Implant to be implanted in bone tissue or in bone tissue supplemented with bone substitute material
6,918,766 Method, arrangement and use of an implant for ensuring delivery of bioactive substance to the bone and/or tissue surrounding the implant
6,913,621 Flexible implant using partially demineralized bone
6,899,734 Modular implant for fusing adjacent bone structure
6,860,884 Implant for bone connector
6,852,129 Adjustable bone fusion implant and method
6,802,845 Implant for bone connector
6,786,908 Bone fracture support implant with non-metal spacers
6,767,367 Spinal fusion implant having deployable bone engaging projections
..761 ,738 Reinforced molded implant formed of cortical bone 6,755,832 Bone plate implant
6,730,129 Implant for application in bone, method for producing such an implant, and use of such an implant
6,689,167 Method of using spinal fusion device, bone joining implant, and vertebral fusion implant
6,689,136 Implant for fixing two bone fragments to each other
6,666,890 Bone hemi-lumbar interbody spinal implant having an asymmetrical leading end and method of installation thereof
6,652,592 Segmentally demineralized bone implant
6,648,917 Adjustable bone fusion implant and method
6,607,557 Artificial bone graft implant
6,599,322 Method for producing undercut micro recesses in a surface, a surgical implant made thereby, and method for fixing an implant to bone
6.562.074 Adjustable bone fusion implant and method 6,562,073 Spinal bone implant
D473,944 Bone implant
6,540,770 Reversible fixation device for securing an implant in bone
6,537,277 Implant for fixing a bone plate
6,506,051 Bone implant with intermediate member and expanding assembly
6,478,825 Implant, method of making same and use of the implant for the treatment of bone defects
6,458,136 Orthopaedic instrument for sizing implant sites and for pressurizing bone cement and a method for using the same
6,447,545 Self-aligning bone implant 6.436.146 Implant for treating ailments of a joint or a bone
6,371,986 Spinal fusion device, bone joining implant, and vertebral fusion implant
6,370,418 Device and method for measuring the position of a bone implant
6,364,880 Spinal implant with bone screws
6,350,283 Bone hemi-lumbar interbody spinal implant having an asymmetrical leading end and method of installation thereof
6,350,126 Bone implant
6,287,343 Threaded spinal implant with bone ingrowth openings
6,270,346 Dental implant for bone regrowth
6,248, 109 Implant for interconnecting two bone fragments
6,217,617 Bone implant and method of securing
6,214,050 Expandable implant for inter-bone stabilization and adapted to extrude osteogenic material, and a method of stabilizing bones while extruding osteogenic material
6,213,775 Method of fastening an implant to a bone and an implant therefor
6,206,923 Flexible implant using partially demineralized bone
6,203,545 Implant for fixing bone fragments after an osteotomy
6,149,689 Implant as bone replacement
6,149,688 Artificial bone graft implant
6, 149,686 Threaded spinal implant with bone ingrowth openings
6, 126,662 Bone implant
6,083,264 Implant material for replacing or augmenting living bone tissue involving thermoplastic syntactic foam
6,058,590 Apparatus and methods for embedding a biocompatible material in a polymer bone implant
6,018,094 Implant and insert assembly for bone and uses thereof
5.976.147 Modular instrumentation for bone preparation and implant trial reduction of orthopedic implants
5,906,488 Releasable holding device preventing undesirable rotation during tightening of a screw connection in a bone anchored implant
5,899,939 Bone-derived implant for load-supporting applications
5,895,425 Bone implant
5,890,902 Implant bone locking mechanism and artificial periodontal ligament system
5,885,287 Self-tapping interbody bone implant
5,819,748 Implant for use in bone surgery
5,810,589 Dental implant abutment combination that reduces crestal bone stress
5,759,035 Bone fusion dental implant with hybrid anchor 5,720,750 Device for the preparation of a tubular bone for the insertion of an implant shaft
5,709,683 Interbody bone implant having conjoining stabilization features for bony fusion
5,709,547 Dental implant for anchorage in cortical bone
5,674,725 Implant materials having a phosphatase and an organophosphorus compound for in vivo mineralization of bone
5,658,338 Prosthetic modular bone fixation mantle and implant system
D381,080 Combined metallic skull base surgical implant and bone flap fixation plate
5,639,402 Method for fabricating artificial bone implant green parts
5 ,624,462 Bone implant and method of securing
D378,314 Bone spinal implant
5,607,430 Bone stabilization implant having a bone plate portion with integral cable clamping means
5,571,185 Process for the production of a bone implant and a bone implant produced thereby
5,456,723 Metallic implant anchorable to bone tissue for replacing a broken or diseased bone
5,441,538 Bone implant and method of securing
5,405,388 Bone biopsy implant
5,397,358 Bone implant
5,383,935 Prosthetic implant with self-generated current for early fixation in skeletal bone
5,364,268 Method for installing a dental implant fixture in cortical bone
5,312,256 Dental implant for vertical penetration, adapted to different degrees of hardness of the bone
* - The preceding patents are all hereby incorporated by reference in their entirety.
IV. Cells for In vitro and Ex vivo Applications A. Stem Cells
In accordance with the present invention, stem cells are provided that may be treated to produce osteogenic cells. Stem cells are generally defined as pluripotent cells that may be induced to differentiate into a particular cell type - in this case, bone forming cells. Various stem cells may be utilized in accordance with the present invention, and include mesenchymal stem cells, hematopoietic stem cells, embryonic stem cells, tissue stem cells, and embryonic carcinoma cells. These cells can be isolated by a variety of methods well known in the art, including immunological isolation, physico-chemical isolation, fluorescent activated cell sorting, limiting dilution culture, etc.
B. Osteogenic Precursor Cells Ia addition to the in vivo embodiments described elsewhere in this document, the present invention also provides for the generation of bone ex vivo. In one embodiment, bone precursor cells (osteogenic cells) are produced from stem cells. As used herein, a bone precursor cell is any cell that is capable of differentiating or expanding into an osteoblast cell. The following section describes the characteristics of these cells. Osteogenic or precursor cells are derived from primary sources such as bone marrow or bone. In addition, cells can be derived from several different species, including cells of human, bovine, equine, canine, feline and murine origin.
i. Bone Precursor Cells (Osteoprogenitor cells) Human bone precursor cells are characterized as small-sized cells that express low amounts of bone proteins (osteocalcin, osteonectin, and alkaline phosphatase) and have a low degree of internal complexity (Long et al, 1995). When stimulated to differentiate, these preosteoblast cells become osteoblast in their appearance, size, antigenic expression, and internal structure. Although these cells are normally present at very low frequencies in bone marrow, a process for isolating these cells has been described (Long et al, 1995). U.S. Patent 5,972,703 further describes methods of isolating and using bone precursor cells, and is specifically incorporated herein by reference.
A number of studies indicate that bone marrow derived cells have osteogenic potential. The majority of these investigations point to mesenchymal stem cells (MSC) as undergoing differentiation into osteoblasts when cultured in the presence of bone-active cytokines (Jaiswal et al, 2000; Phinney et al, 1999; Aubin, 1998; Zohar et al, 1997). Mesenchymal stem cells are a pluripotent population capable of generating multiple stromal cell lineages. MSC, as currently used, are a heterogeneous population of cells isolated by plastic adherence, and propagated by low-density passage. Nonetheless, a recent publication indicates the clonal nature of cell fate outcomes in MSC indicating that a single MSC cell can give rise two or three mesenchymal lineages one of which is usually bone cells (Pitenger et al, 1999). These studies are consistent with earlier reports that demonstrated the osteogenic potential of bone marrow stromal cells, in particular the so-called CFU-f from both mice and human (Friedenstein et al, 1968; Reddi and Huggins, 1972; Friedenstein et al, 1982; Ashton et al, 1985; Bleiberg, 1985; Gronthos et al, 1994; Gronthos et al, 1999). Single-cell isolation of human MSC generated clones that express the same surface phenotype as unfractionated MSC (Pittenger et al, 1999). Interestingly, of the 6 MSC clones evaluated, 2 retained osteogenic, chrondrogenic and adipogenic potential; others were bipotent (either osteo- plus chondrogenic potential, or osteo- adipocytic potential) or were uni-lineage (chondrocyte). This suggests that MSC themselves are heterogeneous in nature (although culture conditions also may have led to loss of lineage potential). To date, the self-renewal capacity of MSC remains in question. Nonetheless, these in vitro studies and other in vivo studies (Kadiyala et al, 1997; Petite et al, 2000; Krebsbach et al., 1999) show that MSC can commit to the bone cell lineage and develop to the state of matrix mineralization in vitro, or bone formation in vivo.
ii. Preosteoblasts
Preosteoblasts are intermediate between osteoprogenitor cells and osteoblasts. The show increasing expression of bone phenotypic markers such as alkaline phosphatase (Kale et al, 2000). They have a more limited proliferative capacity, but nonetheless continue to divide and produce more preosteoblasts or osteoblasts.
iii. Osteoblasts
Osteoblasts are differentiated cells of the bone- forming cell lineage. They are large cells, possessing a eccentric nucleus, and produce of the extracellular proteins required for bone formation. They can be obtained from bone as populations of both preosteoblasts and osteoblasts as described in U.S. Serial No. 09/753,043, which is specifically incorporated herein by reference.
iv. Serum-Free Media
Cell culture may be employed using serum-free media for growth of bone- producing cells, and the subsequent conversion of stem cells into bone-forming osteogenic or osteoprogenitor cells. The following section describes attributes and conditions for using serum- free media. See also U.S. Patent 6,811,776. The use of serum-free culture for the manufacture of recombinant biopharmaceuticals from mammalian cells has been thoroughly reviewed (Barnes, 1987; Barnes & Sam, 1980; Broad et al, 1991; Jayme, 1991). The list of the main additives which are used as supplements for serum-free media is summarized by Barnes (1987) and Barnes & Sam (1980). Most commercially available serum-free media contain a carrier protein such as albumin. The presence of carrier protein might be required for protection of the cell viability.
An example of serum free culture medium can be found in U.S. Patent 5,063,157, herein incorporated by reference. The media comprises, in addition to the base medium, transferrin, insulin, a peptone, a β-D-xylopyranose derivative, selenite and a biological polyamine. Another serum free cell growth medium for mammalian cells is disclosed in U.S. Patent 4,443,546. This growth medium, in addition to the basic medium, contains seven ingredients. EPA 481 791 discloses a culture medium for CHO cells comprising water, an osmolality regulator, a buffer, an energy source, amino acids, an iron source, a growth factor and other optional components. The two media exemplified contain 19 and 17 components, respectively. Examples of potential additives to serum free media follow below.
Albumin. Albumin is preferably supplied in the form of bovine (BSA) or human serum albumin (HSA) in an effective amount for the growth of cells. Albumin provides a source of protein in the media. Albumin is thought to act as a carrier for trace elements and essential fatty acids. Preferably, the albumin used in the present formulations is free of pyrogens and viruses, and when necessary, is approved regulatory agencies for infusion into human patients. The HSA may be deionized using resin beads prior to use. The concentration of human serum albumin is 1-8 mg/ml, preferably 3-5 mg/ml, most preferably 4 mg/ml.
Soluble Carrier/Fatty Acid Complex. The albumin mentioned above could be substituted by a soluble carrier/essential fatty acid complex and a soluble carrier cholesterol complex which can effectively deliver the fatty acid and cholesterol to the cells. An example of such a complex is a cyclodextrin/linoleic acid, cholesterol and oleic acid complex. This is advantageous as it would allow for the replacement of the poorly characterized albumin with a well defined molecule. The use of cyclodextrin removes the need for the addition of human/animal serum albumin, thereby eliminating any trace undesired materials which the albumin would introduce into the media. The use of cyclodextrin simplifies the addition of specific lipophilic nutrients to a serum-free culture.
The lipophilic substances which can be complexed with cyclodextrin include unsaturated fatty acids such as linoleic acid, cholesterol and oleic acid. The linoleic acid, cholesterol and oleic acid are present in effective amounts and can be present in equal proportions such that the total amount is 0.001 to 100 μg/ml, preferably 0.1 to 10 μg/ml. The preparation of such complexes is known in the art and is described, for example, in U.S. Patent 4,533,637, the entire contents of which is hereby incorporated by reference. Iron Source. A source of iron in an effective amount and in a form that can be utilized by the cells can be added to the media. The iron can be supplied by saturating transferrin, its carrier molecule, in an effective amount. The transferrin may be derived from animal sera or recombinantly synthesized. It is understood that when transferrin is derived from an animal source, it is purified to remove other animal proteins, and thus is usually at least 99% pure. The transferrin concentration is usually between 80 and 500 μg/ml, preferably between 120 and 500 μg/ml, more preferably between 130 and 500 μg/ml, even more preferably between 275 and 400 μg/ml and most preferably 300 μg/ml. An iron salt, preferably a water soluble iron salt, such as iron chloride (e.g., FeCl3.6H2O) dissolved in an aqueous solution such as an organic acid solution (e.g. , citric acid) is used to supply the iron to transferrin. One mole of iron chloride is usually used for every mole of citric acid. The concentration of iron chloride is 0.0008 to 8 μg/ml, preferably 0.08 to 0.8 μg/ml, most preferably 0.08 μg/ml.
Insulin Growth Factor. Insulin also may be added to the media of the present invention in an effective amount. The insulin concentration is between 0.25 and 2.5 U/ml, more preferably 0.4-2.1 U/ml, most preferably 0.48 U/ml. In the conversion of Units to mass, 27 U=I mg. Therefore, incorporating the conversion, the insulin concentration is approximately between 9.26 μg/ml and 92.6 μg/ml, more preferably 14.8 μg/ml-77.8 μg/ml, most preferably 17.7 μg/ml. It is again understood that human insulin is more preferable than animal insulin. Highly purified recombinant insulin is most preferred. An insulin like growth factor such as insulin like growth factor 1 and insulin like growth factor 2 may be used in place of or in addition to insulin in an amount which provides substantially the same result as a corresponding amount of insulin. Thus, the term "insulin growth factor" includes both insulin and insulin like growth factors.
Additional Components. The addition of other lipids to the above essential reagents could enhance the proliferative potential of precursor cells. These components, however, are preferably not added unless they are necessary for a particular experiment or to grow a particular type of cell. Optionally, triglycerides and/or phospholipids may be included as additional sources of lipid. A preferable source of lipid contains a mixture of neutral triglycerides of predominantly unsaturated fatty acids such as linoleic, oleic, palmitic, linolenic, and stearic acid. Such a preparation may also contain phosphatidylethanolamine and phosphatidylcholine. Another source of lipid is a human plasma fraction precipitated by ethanol and preferably rendered virus free by pasteurization.
Other ingredients which can optionally be added to the media are cited in the following references: WO 95/06112, U.S. Patent 4,533,637, U.S. Patent 5,405,772. The entire contents of all of these references are incorporated by reference.
Undesired Components. When the media is to be used to grow cells for introduction into a human patient, the media preferably does not contain ingredients such as bovine serum albumin, mammalian serum, and/or any natural proteins of human or mammalian origin (as explained above). It is preferable that recombinant or synthetic proteins, if they are available and of high quality, are used. Most preferably, the amino acid sequences of the recombinant or synthetic proteins are identical to or highly homologous with those of humans. Thus, the most preferable serum-free media formulations herein contain no animal-derived proteins and do not have even a non-detectable presence of animal protein. In the most ideal system, optional components which are not necessary are preferably not added to the medium. Such optional components are described in the prior art cited above and may be selected from the group consisting of meat extract, peptone, phosphatidylcholine, ethanolamine, anti-oxidants, deoxyribonucleosides, ribonucleosides, soy bean lecithin, corticosteroids, myoinositol, monothioglycerol, and bovine or other animal serum albumin.
V. Polymers for Implanting of Bone Cells
As discussed above, bone cells stimulated with Cathepsin K antagonists of the present invention may be used for autologous or heterologous transplant into subjects in need thereof. In many embodiments, supports will be used to provide a scaffold or matrix over with bone cells and grown and deposit bone. Over the last decade there has been a tremendous increase in applications for polymeric materials, including in vivo medical applications. These materials are well suited to implantation as they can serve as a temporary scaffold to be replaced by host tissues, degrade by hydrolysis to non-toxic products, and be excreted, as described by Kulkarni et al. (1971) and Hollinger and Battistone (1986).
Either natural or synthetic polymers can be used to form the matrix, although synthetic polymers are preferred for reproducibility and controlled release kinetics. Synthetic polymers that can be used include bioerodible polymers such as poly(lactide) (PLA), poly(glycolic acid) (PGA), poly(lactide-co-glycolide) (PLGA), and other poly(alpha-hydroxy acids), poly(caprolactone), polycarbonates, polyamides, polyanhydrides, polyamino acids, polyortho esters, polyacetals, polycyanoacrylates and degradable polyurethanes, and non-erodible polymers such as polyacrylates, ethylene-vinyl acetate polymers and other acyl substituted cellulose acetates and derivatives thereof, non-erodible polyurethanes, polystyrenes, polyvinyl chloride, polyvinyl fluoride, poly( vinyl imidazole), chlorosulphonated polyolifins, polyethylene oxide, polyvinyl alcohol, and nylon. Although non-degradable materials can be used to form the matrix or a portion of the matrix, they are not preferred. Examples of natural polymers include proteins such as albumin, fibrin or fibrinogen, collagen, synthetic polyamino acids, and prolamines, and polysaccharides such as alginate, heparin, and other naturally occurring biodegradable polymers of sugar units.
Four polymers widely used in medical applications are poly(paradioxanone) (PDS), poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and PLAGA copolymers. Copolymerization enables modulation of the degradation time of the material. By changing the ratios of crystalline to amorphous polymers during polymerization, properties of the resulting material can be altered to suit the needs of the application. These polymers, including poly(lactide-co-glycolic) acid (PLGA), have been used as polymer composites for bone replacement as reported by Elgendy et al. (1993). Substituted polyphosphazenes have been shown to support osteogenic cell growth, as reported by Laurencin et al. (1993). Poly(organophosphazenes) are high molecular weight polymers containing a backbone of alternating phosphorus and nitrogen atoms. There are a wide variety of polyphosphazenes, each derived from the same precursor polymer, poly(dichlorophosphazene). The chlorine-substituted species can be modified by replacement of the chlorine atoms by different organic nucleophiles such as o-methylphenoxide along with amino acids. The physical and chemical properties of the polymer can be altered by adding various ratios of hydrolytic sensitive side chains such as ethyl glycinate, as described by Wade et al. (1978) and Allcock and Fuller (1981). This will affect the degradation of the polymer as an implantable and biodegradable material as well as vary the support of osteogenic cells for bone and tissue implants, as shown by Laruencin et al (1993).
PLA, PGA and PLA/PGA copolymers are particularly useful for forming the biodegradable matrices. PLA polymers are usually prepared from the cyclic esters of lactic acids. Both L(+) and D(-) forms of lactic acid can be used to prepare the PLA polymers, as well as the optically inactive DL-lactic acid mixture of D(-) and L(+) lactic acids. Methods of preparing polylactides are well documented in the patent literature. The following U.S. Patents, the teachings of which are hereby incorporated by reference, describe in detail suitable polylactides, their properties and their preparation: U.S. Patents 1,995,970; 2,703,316; 2,758,987; 2,951,828; 2,676,945; 2,683,136; and 3,531,561. PGA is the homopolymer of glycolic acid (hydroxyacetic acid). In the conversion of glycolic acid to poly(glycolic acid), glycolic acid is initially reacted with itself to form the cyclic ester glycolide, which in the presence of heat and a catalyst is converted to a high molecular weight linear-chain polymer. PGA polymers and their properties are described in more detail in "Cyanamid Research Develops World's First Synthetic Absorbable Suture," Chemistry and Industry, 905 (1970).
The erosion of the matrix is related to the molecular weights of PLA, PGA or PLA/PGA. The higher molecular weights, weight average molecular weights of 90,000 or higher, result in polymer matrices which retain their structural integrity for longer periods of time; while lower molecular weights, weight average molecular weights of 30,000 or less, result in both slower release and shorter matrix lives. Poly(lactide-co-glycolide) (50:50), degrades in about six weeks following implantation. All polymers for use in the matrix must meet the mechanical and biochemical parameters necessary to provide adequate support for the cells with subsequent growth and proliferation. The polymers can be characterized with respect to mechanical properties such as tensile strength using an Instron tester, for polymer molecular weight by gel permeation chromatography (GPC), glass transition temperature by differential scanning calorimetry (DSC) and bond structure by infrared (IR) spectroscopy, with respect to toxicology by initial screening tests involving Ames assays and in vitro teratogenicity assays, and implantation studies in animals for immunogenicity, inflammation, release and degradation studies. These polymers are particularly useful in forming fibrous or sponge type matrices for implantation. Polymers can also be used to form hydrogels in which the cells are suspended and then implanted.
A. Other Matrix Materials Another class of materials for making the matrix is hydroxyapatite, or a similar ceramic formed of tricalcium phosphate (TCP) or calcium phosphate (CaPO4). Calcium hydroxyapatites occur naturally as geological deposits and in normal biological tissues, principally bone, cartilage, enamel, dentin, and cementum of vertebrates and in many sites of pathological calcifications such as blood vessels and skin. Synthetic calcium hydroxyapatite is formed in the laboratory either as pure Caio (PO4)6 (OH)2 or hydroxyapatite that is impure, containing other ions such as carbonate, fluoride, chloride for example, or crystals deficient in calcium or crystals in which calcium is partly or completely replaced by other ions such as barium, strontium and lead. Essentially none of the geological and biological apatites are "pure" hydroxyapatite since they contain a variety of other ions and cations and may have different ratios of calcium to phosphorous than the pure synthetic apatites.
In general, the crystals of pure synthetic apatites, geological apatites and many impure synthetically produced apatites are larger and more crystalline than the biological crystals of bone, dentin, cementum and cartilage. The crystals of bone, dentin and cementum are very small, irregularly shaped, very thin plates whose rough average dimensions are approximately 10 to 50 angstroms in thickness, 30 to 150 angstroms in width, and 200 to 600 angstroms in length. The synthetic materials are highly diverse, as reported in the literature. For example, the characterization of four commercial apatites was reported by Pinholt et al. (1992); Marden et al. (1990) reports on a protein, biodegradable material; Pinholt et al. (1991) reports on the use of a bovine bone material called Bio-Oss™; Friedman et al. (1991) and Costantino et al. (1991) report on a hydroxyapatite cement; Roesgen (1990) reports on the use of calcium phosphate ceramics in combination with autogenic bone; Ono et al. (1990) reports on the use of apatite-wollastonite containing glass ceramic granules, hydroxyapatite granules, and alumina granules; Passuti et al. (1989) reports on macroporous calcium phosphate ceramic performance; Harada (1989) reports on the use of a mixture of hydroxyapatite particles and tricalcium phosphate powder for bone implantation; Ohgushi et al. (1989) reports on the use of porous calcium phosphate ceramics alone and in combination with bone marrow cells; Pochon et al. (1986) reports on the use of beta-tricalcium phosphate for implantation; and Glowacki et al. (1985), reports on the use of demineralized bone implants.
As used herein, all of these materials are generally referred to as "hydroxyapatite." In the preferred form, the hydroxyapatite is particles having a diameter between approximately ten and 100 μm in diameter, most preferably about 50 μm in diameter. Another form of hydroxyapatite scaffold is devitalized coral as a scaffold. Le Guehennec et al. (2004); Chen et al. (2004); Devecioglu et al. (2004); Kujala et α/. (2004).
Calcium phosphate ceramics can be used as implants in the repair of bone defects because these materials are non-toxic, non-immunogenic, and are composed of calcium and phosphate ions, the main constituents of bone (Frame, 1987; Parsons et al, 1988). Both tricalcium phosphate (TCP) Ca3(PO4)2 and hydroxyapatite (HA) Ca1O (PO4)<5 (OH2) have been widely used. Calcium phosphate implants are osteoinductive, and have the apparent ability to become directly bonded to bone. As a result, a strong bone-implant interface is created.
Calcium phosphate ceramics have a degree of bioresorbability which is governed by their chemistry and material structure. High density HA and TCP implants exhibit little resorption, while porous ones are more easily broken down by dissolution in body fluids and resorbed by phagocytosis. However, TCP degrades more quickly than HA structures of the same porosity in vitro. HA is relatively insoluble in aqueous environments. However, the mechanical properties of calcium phosphate ceramics make them ill-suited to serve as a structural element under load bearing circumstances. Ceramics are not preferred since they are brittle and have low resistance to impact loading.
B. Polymers for Forming Hydrogels
Polymers that can form ionic hydrogels which are malleable can also be used to support the cells. Injecting a suspension of cells in a polymer solution may be performed to improve the reproducibility of cell seeding throughout a device, to protect the cells from shear forces or pressure induced necrosis, or to aid in defining the spatial location of cell delivery. The injectable polymer may also be utilized to deliver ells and promote the formation of new tissue without the use of any other matrix. In a preferred embodiment, the hydro gel is produced by cross-linking the ionic salt of a polymer with ions, whose strength increases with either increasing concentrations of ions or polymer. The polymer solution is mixed with the cells to be implanted to form a suspension, which is then injected directly into a patient prior to polymerization of the suspension. The suspension subsequently polymerizes over a short period of time due to the presence in vivo of physiological concentrations of ions such as calcium in the case where the polymer is a polysaccharide such as alginate.
A hydrogel is defined as a substance formed when an organic polymer (natural or synthetic) is cross-linked via covalent, ionic, or hydrogen bonds to create a three- dimensional open-lattice structure which entraps water molecules to form a gel. Examples of materials which can be used to form a hydrogel include polysaccharides such as alginate, polyphosphazenes, and polyacrylates such as hydroxyethyl methacrylate (HEMA), which are cross-linked ionically, or block copolymers such as Pluronics™ or Tetronics™, polyethylene oxide-polypropylene glycol block copolymers which are cross-linked by temperature or pH, respectively. Other materials include proteins such as fibrinogin, collagen, polymers such as polyvinylpyrrolidone, hyaluronic acid and collagen.
In general, these polymers are at least partially soluble in aqueous solutions, such as water, buffered salt solutions, or aqueous alcohol solutions, that have charged side groups, or a monovalent ionic salt thereof. Examples of polymers with acidic side groups that can be reacted with cations are poly(phosphazenes), poly(acrylic acids), poly(methacrylic acids), copolymers of acrylic acid and methacrylic acid, poly(vinyl acetate), and sulfonated polymers, such as sulfonated polystyrene. Copolymers having acidic side groups formed by reaction of acrylic or methacrylic acid and vinyl ether monomers or polymers can also be used. Examples of acidic groups are carboxylic acid groups, sulfonic acid groups, halogenated (preferably fluorinated) alcohol groups, phenolic OH groups, and acidic OH groups. Examples of polymers with basic side groups that can be reacted with anions are poly(vinyl amines), poly(vinyl pyridine), polyvinyl imidazole), and some imino substituted polyphosphazenes. The ammonium or quaternary salt of the polymers can also be formed from the backbone nitrogens or pendant imino groups. Examples of basic side groups are amino and imino groups.
Alginate can be ionically cross-linked with divalent cations, in water, at room temperature, to form a hydrogel matrix. Due to these mild conditions, alginate has been the most commonly used polymer for hybridoma cell encapsulation, as described, for example, in U.S. Patent 4,352,883. Described therein is an aqueous solution containing the biological materials to be encapsulated is suspended in a solution of a water soluble polymer, the suspension is formed into droplets which are configured into discrete microcapsules by contact with multivalent cations, then the surface of the microcapsules is cross-linked with polyamino acids to form a semipermeable membrane around the encapsulated materials.
The polyphosphazenes suitable for cross-linking have a majority of side chain groups which are acidic and capable of forming salt bridges with di- or trivalent cations. Examples of preferred acidic side groups are carboxylic acid groups and sulfonic acid groups. Hydrolyrically stable polyphosphazenes are formed of monomers having carboxylic acid side groups that are cross-linked by divalent or trivalent cations such as Ca2+ or Al3+. Polymers can be synthesized that degrade by hydrolysis by incorporating monomers having imidazole, amino acid ester, or glycerol side groups. Bioerodible polyphosphazenes have at least two differing types of side chains, acidic side groups capable of forming salt bridges with multivalent cations, and side groups that hydrolyze under in vivo conditions, e.g., imidazole groups, amino acid esters, glycerol and glucosyl.
The water soluble polymer with charged side groups is cross-linked by reacting the polymer with an aqueous solution containing multivalent ions of the opposite charge, either multivalent cations if the polymer has acidic side groups or multivalent anions if the polymer has basic side groups. The preferred cations for cross-linking of the polymers with acidic side groups to form a hydrogel are divalent and trivalent cations such as copper, calcium, aluminum, magnesium, strontium, barium, and tin, although di-, tri- or tetra-functional organic cations such as alkylammonium salts can also be used. Aqueous solutions of the salts of these cations are added to the polymers to form soft, highly swollen hydrogels and membranes. The higher the concentration of cation, or the higher the valence, the greater the degree of cross-linking of the polymer. Concentrations from as low as 0.005M have been demonstrated to cross-link the polymer. Higher concentrations are limited by the solubility of the salt. The preferred anions for cross-linking of the polymers to form a hydrogel are divalent and trivalent anions such as low molecular weight dicarboxylic acids, for example, terepthalic acid, sulfate ions and carbonate ions. Aqueous solutions of the salts of these anions are added to the polymers to form soft, highly swollen hydrogels and membranes, as described with respect to cations.
A variety of polycations can be used to complex and thereby stabilize the polymer hydrogel into a semi-permeable surface membrane. Examples of materials that can be used include polymers having basic reactive groups such as amine or imine groups, having a preferred molecular weight between 3,000 and 100,000, such as polyethylenimine and polylysine. These are commercially available. One polycation is poly(L-lysine), examples of synthetic polyamines are polyethyleneimine, poly(vinylamine), and poly(allyl amine). There are also natural polycations such as the polysaccharide, chitosan. Polyanions that can be used to form a semi-permeable membrane by reaction with basic surface groups on the polymer hydrogel include polymers and copolymers of acrylic acid, methacrylic acid, and other derivatives of acrylic acid, polymers with pendant SO3 H groups such as sulfonated polystyrene, and polystyrene with carboxylic acid groups.
VI. Screening Assays In still further embodiments, the present invention provides methods identifying new and useful inhibitors of Cathepsin K for use in stimulating bone production. These assays may comprise random screening of large libraries of candidate substances; alternatively, the assays may be used to focus on particular classes of compounds selected with an eye towards structural attributes that are believed to make them more likely to modulate the function of Cathepsin K.
By function, it is meant that one may assay for Cathepsin K enzyme activity, expression or bone formation. To identify a Cathepsin K modulator, one generally will determine the function of Cathepsin K in the presence and absence of the candidate substance, a modulator defined as any substance that alters function. For example, a method generally comprises:
(a) providing a candidate modulator;
(b) admixing the candidate modulator with an isolated enzyme, cell lysate or cell, or a suitable experimental animal;
(c) measuring Cathepsin K activity or expression or bone formation; and (d) comparing the characteristic measured in step (c) with that observed in the absence of the candidate modulator, wherein a difference between the measured characteristic indicates that said candidate modulator is, indeed, a modulator of Cathepsin K. Assays may be conducted in cell free systems, in isolated cells, or in organisms including transgenic animals. Bone formation can be identified by the von Koassa or Alzarin Red stains, FTIR or Raman spectrometric analysis, or by fluorochromes linked to compounds that bind bone. U.S. Patent 6,346,373 describes a whole cell based assay for Cathepsin K activity. It will, of course, be understood that all the screening methods of the present invention are useful in themselves notwithstanding the fact that effective candidates may not be found. The invention provides methods for screening for such candidates, not solely methods of finding them.
VII. Examples
The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.
Example 1
Cathepsin K inhibition simulates ex vivo bone formation Velcura's proprietary technology (U.S. Patent 6,811,786) covering human growth in tissue culture (ex vivo bone formation) results in the formation of three-dimensional tissue like aggregates, the up-regulation of bone proteins such as osteonectin and alkaline phosphatase and the formation of human bone (Kale et al., 2000). This core technology provides the ability to rapidly grow human bone in tissue culture. As shown in FIG. 1, this requires human bone cells (osteoblasts) to be grown as 3- dimensional tissue-like aggregates, hi the presence of an osteogenic compound (small molecule or biological) the osteoblasts then produce monophosphate- and carbonate derivatized hydroxyapatite analogous to human bone, as demonstrated via FTIR and Ramen spectrometry (Kale et al., 2000). This bone-formation is detected in a variety of ways; for example, visualization of the calcium in the bone with a fluorescent probe (FIG. 2, arrows). A variety of compounds that inhibit Cathepsin K activity have been developed, hi particular, compounds described in U.S. Patents 5,843,992; 6,387,908; 6,689,785 (incorporated herein by reference) provide for intracellular inhibition. A lead compound, VEL-0230, is an orally available Cathepsin K inhibitor that stimulates ex vivo bone formation (FIG. 2) and both promotes bone formation and prevents bone loss in animal models (see below). Additionally, the inventor has used our ex vivo bone formation technologies to develop other compounds with similar properties to VEL-0230 to investigate as second generation compounds.
Cell-permeation is required for Cathepsin K inhibition and ex vivo bone formation. Another novel aspect of this invention is that compounds that do not enter the cell {i.e., are impermeable) fail to stimulate ex vivo bone formation. This is demonstrated by the comparison of Cathepsin K enzymatic activity in cell lysates versus intact cells.
Human Osteoblast-Based Cathepsin K Assays, hi order to evaluate compounds that inhibit Cathepsin K, the inventor developed assays using the Cathepsin-K specific fluorescent substrate, Z-Gly-Pro-Arg-AMC. The assays were performed in the presence of human osteoblast cell-free lysate (herein referred to as the Lysate assay). As well, we used these inhibitors to treat intact human osteoblasts (for two days) and determined the resultant degree of inhibition in intracellular Cathepsin K activity (Intact cell assay). Comparison of these two assays thus evaluates permeability differences among the compounds, as other data show that these differences are not due to differences in compound stability (not shown).
The inventor statistically evaluated Lysate assay IC50 values for VEL-0230 and the other NC-related compounds, determining the mean as well as the 95% and 99% confidence intervals around these means (Table 1). From this, compounds having an IC50 similar to VEL-0230 were defined as those with a similar shaped concentration response profile as well as an IC5O value that was within the 95% Confidence Interval for this group, i.e., within an IC50 range of 297.8-350.4 nM (FIG. 3 & Table 1). The compounds with IC5Os > 351.0 nM were thus defined as belonging to the "High IC50 Group" and those with IC5Os <298.0 nM were defined as belonging in the "Low IC50 Group." Statistical hypothesis testing validated these classifications. Importantly, the difference between the Low IC50 Group and the Similar IC50 Group is highly significant (p = 2.56 x 10~6; two-tailed Student t-test). The wide variability and low numbers of compounds result in non-significant t-tests between the Similar and High IC50 groups. However, the average IC50 value for the High Group (709.3 nM) is well outside the upper 99% Confidence Interval value of the Similar group, strongly suggesting that this group is significantly different from the VEL-0230 group (FIG. 3). Examination of the effects of these compounds in the In-tact cell assay demonstrates a reduction in cell-permeability (not shown) and similar IC50 to VEL- 0230. Indeed, even the parent compound VEL-0230 shows this characteristic (FIG. 4). Those compounds which were active in the Lysate assay, but cannot enter the cell, fail to stimulate ex vivo bone formation.
Cathepsin K RNA and RNAi Studies. Consistent with the novel mechanism of action of this enzyme within bone forming cells, the inventor identified Cathepsin K as a gene that was consistently down-regulated in response to induction of bone formation with osteogenic growth factors (not shown). To better understand the role of Cathepsin K in human bone formation, then inventor used RNAi to specifically reduce Cathepsin K expression in ex vivo bone formation assays. To accurately assess the effect of silencing Cathepsin K on osteoblast biology, it is important to properly control for the potential off-target effects of transfection and siRNA introduction. To address these concerns, the following controls were used: (1) osteoblasts were mock transfected in the absence of siRNA (Control) to determine the effects of transfection; (2) non-functional siRNAs that minimally interact with the RISC complex (Non- RISC) were introduced to determine the potential off-target affects of transfection; and (3) non- targeting siRNAs that interact with RISC but are bioinformatically designed to minimize possible interaction with human cellular RNA (non-targeting) were used to measure the effect of RISC activation by siRNAs. None of these controls significantly altered Cathepsin K expression or osteoblast phenotype. However, siRNAs targeting Cathepsin K significantly reduce Cathepsin K mRNA levels in human osteoblasts as compared to controls (FIG. 5). Preliminary time course experiments reveal that Cathepsin K silencing reaches maximal levels within 24 hours post-transfection then gradually rise (FIG. 6). As expected, siRNA-mediated inhibition of Cathepsin K RNA results in similar tissue like osteoblast aggregates and bone formation as do either small molecule inhibitors like VEL-0230 or osteogenic growth factors (not shown)
In vivo actions of Cathepsin K inhibitors. Pharmacological studies in rats, intact beagle dogs, medically ovariectomized monkeys and surgically ovariectomized monkey models clearly demonstrate that the Cathepsin K inhibitor VEL-0230 both stimulates bone formation and retards its loss. The compound shows clear inhibition of bone resorption in in vivo models. In ovariectomy models, urinary excretion of bone resorption markers type 1 collagen cross-linked N- or C-telopeptide (NTx, CTx) are decreased and serum levels of bone specific alkaline phosphatase (BSAP; a marker of bone formation) are increased. In addition, bone and bone strength both increase (data not shown).
As expected, bone loss in ovariectomized rats results in reduced trabecular bone content (FIG. 7, left vs. center panel), whereas treatment with VEL-0230 prevents this loss (right panel). Likewise, measurement of the changes in cortical bone thickness indicates a clear decrease in ovariectomized animals. (FIG. 8), and increased bone mineral density (BMD) and bone strength of tibia and the 5th lumbar vertebral (not shown). VEL-0230 also significantly inhibits increases in rat urinary excretion of the urinary bone resorption markers.
The inventor also investigated an osteoporosis prevention model in chronically-treated Cynomolgus monkeys: sham-operated (Sham), ovariectomized (OVX) and OVX VEL-0230-treated animals are evaluated. Overall, the VEL-0230 biomarker and density data support an anabolic effect of VEL-0230 treatment. Biochemical markers of both bone formation are significantly elevated in treated animals and resorption markers are significantly decreased (bone resorption markers not shown). VEL-0230 treated OVX animals show marked increases in the bone formation markers osteocalcin (FIG. 8A, OC; 400% to 800%) and in bone-specific alkaline phosphatase (FIG. 8B, BSAP; 40%-60%). The increase in OVX animals is expected, as it is being driven by the increased resorption (increased OC in Sham animals remains unexplained). The OVX animals show significant reductions in bone mineral density (BMD) whereas the Sham treated animals show no significant changes. In contrast, VEL-0230 treated animals show a later but marked, albeit not yet significant, increase in BMD the higher dose treatment group and a modest increase in BMD in the low dose animals in weeks 16-32 (FIG. 8C). The inventor concludes that VEL-0230 treatment provides unambiguous evidence that the compound is bio-logically active in non-human primates.
Example 2
Data Analysis. Raw gene chip data was imported into the Gene Spring software package (www.silicongenet-ics.com) for statistical analysis. Data transformation was performed with values less than 0.01 set to 0.01. To control for chip-wide variation in staining intensity, per chip normalization was performed with all measurements on the chip divided by the 50% percentile value. To account for differences in detection efficiency between probe sets, signal intensity for each probe set in the sample was divided by the median signal intensity for that probe set in the experimental group. Genes that vary significantly across the data set were identified using a paired t-test. At this level of discrimination, TGF-βl, a powerful and pleiotropic growth factor, induces ex vivo bone formation has features in common with other members of the TFG-β super-family; however, other osteogenic growth factors do display distinct expression implying both factor-specific and common pathway genes can (eventually) be identified. (FIG. 10) This data set represents 8600 differentially regulated genes. To more precisely define the set of responding genes further selection criteria were applied.
Definition of Modulated Gene Expression. To identify genes whose expression is significantly altered in response to osteogenic growth factor induction, each induction group was analyzed individually with Affymetrix HU133 chip sets (resulting in 6 data sets: IGF-I, PTH, Vitamin D3, and TGF-β Days 1, 3, and 5). To be included in the gene list, a probe set had to have a two-tailed p-vahie less than or equal to 0.05 from the paired t-test. hi addition, the probe set had to:
• have a ratio of induced to control >2 (or <0.5) in at least 75% of the samples in the induction group
• have an average ratio of induced: to control >2 (or <0.5) in the induction group
Probe sets representing 1245 genes met the statistical and filtering criteria listed above. These genes (and others see next) were utilized to construct a custom Affymetrix gene array, the OsteoChip™. Importantly, 15% of the osteogenic genes discovered by the inventor cover a wide array of physiologically relevant proteins, including both secreted proteins and membrane proteins that are suitable as targets for pharmaceuticals (e.g., receptors, kinases, signaling molecules). Analysis of these gene indicated further refinement into categories of possible molecular tar-gets for therapeutic intervention (FIG. 11).
Velcura's OsteoChip™. Based on extensive analysis of bone gene expression (genome-wide, see below) in normal individuals (n = 9), Velcura designed the OsteoChip™, a DNA microarray that was produced under contract by Affymetrix Inc. utilizing its proprietary technology. These arrays contain oligomeric representatives of all of the genes identified by Velcura as being important to human bone formation. This microarray includes those genes (i.e., probe sets) discovered as detailed above as being involved in human bone formation. It also contains an additional 250 genes described in the scientific literature as being involved in bone formation (also below) Bone-associated genes. Five-hundred bone-associated genes were identified from searches of the literature, LocusLink, Online Mammalian Inheritance in Man, Mouse Mutation and Knockout Database, and the Skeleton Expression Database. Of these, 250 were observed to be differentially modulated in induced osteoblasts via the above criteria. The remaining 250 genes are represented by 621 probe sets. After removing redundant probe sets, 316 probe sets, representing these 250 additional bone-associated genes, were included on the OsteoChip™. Additionally, 100 probe sets having an average ratio of induced: control of 1.02 and an average coefficient of variation of 16.9% were included on the Osteo-Chip™ as controls.
Cellular Pathway Mapping. The net result of using the OsteoChip™ is the reduction of the analyzed gene pool from the 20,000 or 30,000 genes in the human genome to 1281. This greatly enhances the rapidity with which one can analyze anabolic compounds. Nonetheless, examination of this reduced number of genes is meaningless unless they are put into a context of cellular signaling pathways. Thus, the inventor utilizes pathway analysis programs to identify both novel path-ways (not shown) and canonical pathways that are activated during ex vivo bone formation (FIG. 12).
Molecular Signature of Bone Formation. RNA expression profiling was used to deter-mine the molecular response of human osteo-blasts following induction of bone formation with osteogenesis promoting compounds. Osteoblasts from fifteen independent donors were induced with TGF-βl (n=14), BMP-2 (n=6), BMP-7 (n=3), and Vitamin-D3 (n=6) and analyzed using the OsteoChip™. Statistical analyses were performed as described above to identify genes that were modulated in response to induction. Further, genes that are regulated in a similar manner by all of the bone stimulatory factors were identified. The inventor believes these 165 genes represent a molecular signature of bone formation. These genes, as well as modulated genes for each induction group, have been mapped onto cellular pathways and networks using GeneGO to identify the cellular processes that are activated during bone formation. Pathway mapping has identified not only pathways known to be modulated during bone formation (e.g., the Wnt signaling pathway), but also novel pathways and networks not previously associated with bone formation (not shown). These pathways and their regulators provide key entry points for RNA interference (RNAi)- based reverse genetics to further expand our understanding of bone formation.
All of the compositions and/or methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions and/or methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims. VIII. References
The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.
U.S. Patent 1,995,970 U.S. Patent 2,676,945 U.S. Patent 2,683,136 U.S. Patent 2,703,316 U.S. Patent 2,758,987 U.S. Patent 2,951,828 U.S. Patent 3,531,561 U.S. Patent 4,352,883 U.S. Patent 4,443,546 U.S. Patent 4,533,637 U.S. Patent 5,063,157 U.S. Patent 5,399,363 U.S. Patent 5,405,772 U.S. Patent 5,466,468 U.S. Patent 5,543,158 U.S. Patent 5,580,579 U.S. Patent 5,629,001 U.S. Patent 5,641,515 U.S. Patent 5,792,451 U.S. Patent 5,843,992 U.S. Patent 5,843,992 U.S. Patent 5,861,298 U.S. Patent 5,972,703 U.S. Patent 6,274,336 U.S. Patent 6,346,373 U.S. Patent 6,387,908 U.S. Patent 6,462,076 U.S. Patent 6,531,612 U.S. Patent 6,537,514 U.S. Patent 6,613,308
U.S. Patent 6,642,239
U.S. Patent 6,689,785
U.S. Patent 6,689,785
U.S. Patent 6,811,776
U.S. Patent 6,811,786
U.S. Pubn. 2004/0249153
U.S. Pubn. 2005/0054819
U.S. Pubn. 2005/0107616
U.S. Pubn. 2005/0245596
U.S. Pubn. 2006/0020001
U.S. Pubn. 2006/0074092
U.S. Serial 09/753,043
Allcock and Fuller, J. Am. Chem. Soc, 103:2250-2256, 1981.
Ashton et α/., Bone, 6:313-319,1985.
Aubin, Biochem. Cell Biology, 76:899-910,1998.
Barnes and Sam, Cell, 22:649-655, 1980.
Barnes, Bio. Techniques, 5: 534-542, 1987.
Bleiberg, Connect Tissue Res., 14:121-127,1985.
Bossard et al, J. Biol. Chem., 271(21):12517-12524, 1996.
Broad et al, Cytotechnology 5:47-55, 1991.
Chen et al, Brit. J. Oral & Maxillofacial Surg. 42(6):532-7, 2004.
Costantino et al., Arch. Otolaryngol. Head Neck Surg., 117(4):379-384, 1991.
Cynamid Research Develops World's First Synthetic Absorbable Suture, Chemistry and
Industry , 905, 1970.
Devecioglu et al., J. Biomat. App. 19(2): 107-20, 2004. Dodds, Cell Biochem. Function, 21:231-234, 2003. Elgendy et al, Biomaterials, 14:263-269, 1993. EP 481 791
Frame, Int. J. Oral Maxillofac. Surg, 16(6):642-655, 1987. Friedenstein et al, Exp. Hematol, 10:217-227,1982. Friedenstein et al, Transplantation, 6:230-247,1968.
Friedman et al, Arch. Otolaryngol. Head Neck Surg., 117(4), 386-389, 1991. Glowacki et al, CHn. Plast. Surg., 12(2), 233-241, 1985. Grabowskal et al, Curr. Opin. DrugDiscov. Devel, 8(5):619-630, 2005.
Gronthos et al, Blood, 84:4164-4173,1994.
Gronthos et al, J. Bone Min. Res., 14:47-56,1999.
Harada, Shikwa-Gakuho, 89(2):263-297, 1989.
Hollinger and Battistone, Clinical Orthop. ReI. Res., 207:290-305, 1986.
Hwang et al., Crit. Rev. Ther. Drug Carrier Syst, 15(3):243-284, 1998.
Jaiswal et al, J. Biol. Chem., 275:9645-9652, 2000.
Jayme, Cytotechnology 5(1): 15-30, 1991.
Kadiyala et al, Cell Transplantation, 6:125-134,1997.
Kale et al, Nat. Biotech., 18:954-958, 2000.
Kane and Gottesman, Cancer Biology, 1:127-136, 1990.
Krebsbach et al, Crit. Rev. Oral Biol. Med., 10:165-181,1999.
Kujala et al, Arch. Orthopaedic & Trauma Surg. 124(l):26-30, 2004.
Kulkarni et al, J. Biom. Mater. Res., 5:169-81, 1971.
Laurencin et al, J. Biom. Mater. Res., 27(7):963-973, 1993.
Le Guehennec et al, European Cells & Materials, 8:1-10, 2004.
Littlewood-Evans et al, Bone, 20:81-86, 1997.
Long, J CHn. Invest, 95:881-887, 1995.
Mandelin et al, Human osteoblasts produce Cathepsin K. Bone; in press, 2006.
Marden et al, J. Craniofac. Surg, 1(3): 154- 160, 1990.
Marx, Science, 235:285-286, 1987.
Mathiowitz et al, Nature, 386(6623):410-414, 1997.
McQueney et al, J. Biol. Chem., 272:13955-13960, 1997.
Ohgushi et al, Acta Orthop. Scand., 60(3):334-339, 1989.
Ono et al, Biomaterials, 11(4):265-271, 1990.
Parsons et al, Ann. NY Acad. ScL, 523:190-207, 1988.
Passuti et al, Clin. Orthop., 248:169-176, 1989.
PCT Appln. WO 2005/049028
Petite et al, Nat. Biotech., 18:959-963,2000.
Phinney et al, J. Cellular Biochem., 75:424-436,1999.
Pinholt et α/., J. Oral Maxillofac. Surg., 50(8):859-867, 1992.
Pinholt et al, Scand. J. Dent. Res., 99(2):154-161, 1991.
Pittenger et al, Science, 284:143-147,1999.
Pochon et al, Z-Kinderchir., 41(3):171-173, 1986. Reddi and Huggins, Proc. Natl. Acad. Sd. USA, 69:1601-1605,1972.
Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, pp. 1289-
1329, 1990. Remington's Pharmaceutical Sciences, 15th ed., pages 1035-1038 and 1570-1580,
Mack Publishing Company, Easton, PA, 1980. Roesgen, Unfallchirurgle, 16(5):258-265, 1990. Sloan and Honn, Cancer Metastasis Rev., 3:249-263, 1984. Troen, Drug News Perspectives, 17:19-28, 2004.. Wade et ah, In: Organomet. Polym., Carraher et al. (Eds.), Academic Press, NY,
283-288, 1978. WO 95/06112.
Yasuda et al, Adv. Drug Deliv. Rev., 57(7):973-993, 2005. Zaidi et al, J. Bone Mineral Res., 18:599-609, 2003. Zohar et al, Blood, 90:3471-3481,1997.

Claims

1. A method of promoting bone formation comprising:
(i) selecting an intracellular Cathepsin K inhibitor; and
(ii) administering to a subject said first inhibitor of Cathepsin K.
2. The method of claim 1, wherein said inhibitor is a biological or an organopharmaceutical small molecule.
3. The method of claim 2, wherein said first inhibitor is a biological.
4. The method of claim 3, wherein said biological is a peptide, an siRNA, an antisense molecule or a single-chain antibody.
5. The method of claim 2, wherein said inhibitor is an organopharmaceutical small molecule.
6. The method of claim 5, wherein said inhibitor is an epoxysuccinamide and variants thereof.
7. The method of claim 5, wherein said inhibitor is VEL-0230 or analog thereof.
8. The method of claim 5, wherein said inhibitor is a non-epoxysuccinamide.
9. The method of claim 1, further comprising contacting said subject with a second agent.
10. The method of claim 9, wherein said second agent is a bisphosphonate, a PTH analog, or a second inhibitor of Cathepsin K that is distinct from said first inhibitor.
11. The method of claim 10, wherein the second inhibitor of Cathepsin K is an extracellular inhibitor of Cathepsin K.
12. The method of claim 1, wherein said first inhibitor is formulated to increase transmembrane delivery.
13. The method of claim 12, wherein said first inhibitor is formulated with a cell permeability factor.
14. The method of claim 12, wherein said first inhibitor is formulated in a lipid delivery vehicle.
15. The method of claim 12, wherein said first inhibitor is formulated to enhance its bioavailability
16. The method of claim 1, wherein said subject is a human.
17. The method of claim 1, wherein said subject suffers from a bone-related pathology or injury.
18. The method of claim 17, wherein said bone-related pathology is osteoporosis, vitamin D deficiency, bone cancer, bone fracture, periodontal disease, Paget' s disease, osteoporosis secondary to other diseases.
19. The method of claim 1, wherein said first inhibitor also prevents bone resorption.
20. The method of claim 1, wherein said first inhibitor is administered to said subject more than once.
21. The method of claim 1, wherein said first inhibitor is administered to said subject by oral or intravenous routes.
22. The method of claim 1, wherein the subject is a non-human animal. .
23. A method of producing bone in an isolated bone cell comprising: (i) selecting an intracellular Cathepsin K inhibitor;
(ii) contacting said bone cell with said inhibitor of Cathepsin K; and (iii) culturing said cell under conditions promoting bone formation.
24. The method of claim 23, further comprising implanting said bone cell in a subject.
25. The method of claim 24, wherein said bone cell was obtained, prior to step (ii) from said subject.
26. The method of claim 25, wherein said obtained cell was a stem cell prior to step (ii). o Δ,π I . The method of claim 26, wherein said stem cell was cultured under conditions promoting the formation of an osteogenic cell prior to step (ii).
8. A method of identifying an agent that promotes bone formation comprising:
(i) providing a candidate compound;
(ii) admixing the candidate compound with an isolated Cathepsin K enzyme, or a cell expressing Cathepsin K, or an experimental animal, cells of which express Cathepsin K;
(iii) measuring Cathepsin K activity or expression or bone formation; and (iv) comparing the characteristic measured in step (iii) with that observed in the absence of the candidate modulator, wherein a difference between the measured characteristic indicates that said candidate compound is, indeed, a modulator of Cathepsin K.
EP07797567A 2006-05-22 2007-05-18 Use of cathepsin k antagonists in bone production Withdrawn EP2019688A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74788606P 2006-05-22 2006-05-22
US81045606P 2006-06-01 2006-06-01
PCT/US2007/069211 WO2007137149A2 (en) 2006-05-22 2007-05-18 Use of cathepsin k antagonists in bone production

Publications (1)

Publication Number Publication Date
EP2019688A2 true EP2019688A2 (en) 2009-02-04

Family

ID=38724028

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07797567A Withdrawn EP2019688A2 (en) 2006-05-22 2007-05-18 Use of cathepsin k antagonists in bone production

Country Status (5)

Country Link
EP (1) EP2019688A2 (en)
JP (1) JP2010503610A (en)
AU (1) AU2007253796A1 (en)
CA (1) CA2652600A1 (en)
WO (1) WO2007137149A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102369276B (en) * 2009-02-20 2015-02-04 文特里亚生物科学公司 Cell Culture Media Containing Protein Combinations
JP2012148978A (en) * 2009-09-24 2012-08-09 Nippon Chemiphar Co Ltd Preventive or curative agent of periodontal disease or apical periodontitis
US20130157356A1 (en) * 2010-01-25 2013-06-20 Ventria Bioscience Methods & compositions for improving protein production
CN103381152A (en) * 2013-02-05 2013-11-06 吉林省金梓源生物科技有限公司 Application of myricetin used as cathepsin K inhibitor

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843992A (en) * 1995-03-31 1998-12-01 Nippon Chemiphar Co., Ltd. Epoxysuccinic acid derivatives
CA2209109A1 (en) * 1995-10-30 1997-05-09 Thomas Joseph . Carr Method of inhibiting cathepsin k
JP4336039B2 (en) * 1997-09-04 2009-09-30 日本ケミファ株式会社 Epoxy succinamide derivatives
SE516949C2 (en) * 1999-12-30 2002-03-26 Scania Cv Ab Alarm system for motor vehicles
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
WO2003013518A1 (en) * 2001-08-03 2003-02-20 Smithkline Beecham Corporation Alpha-ketoamide derivatives as cathepsin k inhibitors
AR036375A1 (en) * 2001-08-30 2004-09-01 Novartis Ag PIRROLO [2,3-D] PIRIMIDINE -2- CARBONITRILE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, A PHARMACEUTICAL COMPOSITION AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF MEDICINES
US7282512B2 (en) * 2002-01-17 2007-10-16 Smithkline Beecham Corporation Cycloalkyl ketoamides derivatives useful as cathepsin K inhibitors
EP1494663A1 (en) * 2002-04-10 2005-01-12 SmithKline Beecham Corporation Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007137149A2 *

Also Published As

Publication number Publication date
JP2010503610A (en) 2010-02-04
WO2007137149A3 (en) 2008-02-14
AU2007253796A1 (en) 2007-11-29
CA2652600A1 (en) 2007-11-29
WO2007137149A2 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
Li et al. Exosomes from adipose-derived stem cells regulate M1/M2 macrophage phenotypic polarization to promote bone healing via miR-451a/MIF
US8299046B2 (en) Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth
EP2167648B1 (en) Methods for optimized expansion and implantation of mesenchymal stem cells
RU2718590C2 (en) Induction of osteogenesis by introduction of rna coding bone morphogenetic protein (bmp)
KR20180074822A (en) Methods of generating, repairing and/or maintaining connective tissue in vivo
EP2753346B1 (en) Ceramidase and cell differentiation
WO2007143139A1 (en) Abcb5 positive mesenchymal stem cells as immunomodulators
Li et al. Bone marrow-derived mesenchymal stem cells in three-dimensional co-culture attenuate degeneration of nucleus pulposus cells
EP2019688A2 (en) Use of cathepsin k antagonists in bone production
EP3311809B1 (en) Use of pharmaceutical composition in preparation of drug for promoting chondrocyte generation
Xia et al. Matrigel scaffold combined with Ad-hBMP7-transfected chondrocytes improves the repair of rabbit cartilage defect
ES2304359T3 (en) PROCEDURE FOR EX-VIVO TRAINING OF MAMPHERE BONES AND USES OF THE SAME
Moioli et al. Autologous stem cell regeneration in craniosynostosis
US20170056556A1 (en) Enhancement of osteogenic potential of bone grafts
JP2006514562A (en) Method for treating diseased tissue, degenerated tissue or damaged tissue using three-dimensional tissue produced in vitro in combination with tissue cells and / or exogenous factors
US20230010110A1 (en) Histatin-1 formulation for the treatment, repair or regeneration of bone tissue in a subject
US11007229B2 (en) Method for inducing transdifferentiation of fibroblasts into chondrocytes
AU2003218463A1 (en) Bone generation by gene therapy
WO2009076490A1 (en) Use of cathepsin l antagonists in the treatment of bone disease
WO2011007135A1 (en) Use of pro-inflammatory compounds for promoting bone formation
Wallmichrath et al. Epidermal growth factor (EGF) transfection of human bone marrow stromal cells in bone tissue engineering
US20140286916A1 (en) Uses of Growth and Differentiation Factor 8 (GDF-8)
WO2010021162A1 (en) Cell preparation for bone tissue regeneration
US20070275462A1 (en) Human Prostate Cancer Cell Factor(s) that Induce Stem Cell Commitment and Osteogenesis
WO2019246013A1 (en) Peptides to enhance bone growth, repair and cell function

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20081126

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101201